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ABSTRACT: Cystic fibrosis is the most common fatal genetic disorder in the Northern 
European population; however early diagnosis and treatment can lead to increased quality and 
length of life for affected individuals and therefore its diagnosis is of great public health 
significance. Cystic fibrosis is a monogenic recessive disorder caused by mutation in the CFTR 
gene. Current screening methods include newborn screening tests and invasive prenatal 
diagnostic tests. Newborn enzymatic screening tests are prone to false positive results, leading to 
unwarranted stress and anxiety for new parents. Invasive prenatal testing is available, but these 
invasive procedures carry some risks including miscarriage which also causes anxiety and stress 
for parents. Non-invasive prenatal testing for fetal aneuploidy using cell-free fetal DNA derived 
from maternal plasma is now part of the regular clinical offering for women in their first 
trimester of pregnancy. No commercial non-invasive prenatal test for monogenic disease is 
currently available. The goal of this study is to develop a non-invasive prenatal test for the 
detection of the mutation status of the fetus. Proposed here are methods to haplotype the parents 
in the CFTR region and to genotype the plasma to establish the mutation status of the fetus. In 
comparison to newborn screening or invasive diagnostic tests, a non-invasive prenatal test for 
cystic fibrosis would have little to no risk and also provide parents more time to identify clinical 
and psychosocial resources to facilitate their family’s needs and decision-making processes. 
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1.0  BACKGROUND 
1.1 PRENATAL SCREENING TESTS 
Prenatal screening tests are designed to indicate whether the possibility of a fetal genetic 
condition is higher or lower than would be expected in the general population. These screenings 
do not serve as a definitive diagnosis of a fetal condition. Currently three types of screening are 
available to pregnant women: Ultrasound, First Trimester Screening, and Multiple Marker 
Screening[1]. These screening methods are not exclusive and many times will be combined. 
Ultrasound 
Ultrasound is used to obtain accurate dating of a pregnancy and to assess fetal growth and 
development. Birth defects resulting from chromosomal abnormalities, such as Down syndrome, 
can be observed as well as other defects not caused by chromosome abnormalities, such as spina 
bifida. Ultrasounds done at 18-20 weeks can detect Down syndrome (50% detection rate), 
Trisomy 18 or 13 (90% detection rate), spina bifida (90% detection rate), and anencephaly 
(100% detection rate)[1]. 
First Trimester Screening (FTS) 
The first trimester screening consists of two parts: an ultrasound and a maternal serum blood test. 
FTS is performed between 11-14 weeks. The ultrasound measures nuchal translucency and the 
blood test measures the levels of pregnancy associated plasma protein (PAPP-A) and total 
human chorionic gonadotrophin (total hCG). Abnormal nuchal translucency and/or abnormal 
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levels of PAPP-A or total hCG can be an indication of Trisomy 18 or Down syndrome.  FTS 
detects 85% of pregnancies with Down syndrome or Trisomy 18[1].  
Multiple Marker Screening (MMS) 
Like FTS, multiple marker screening detects pregnancies at increased risk for Down syndrome 
and Trisomy 18. Additionally it can also identify spina bifida and anencephaly. MMS is done at 
15-20 weeks and is a maternal serum blood test which measures alpha-fetoprotein (AFP), hCG, 
unconjugated estriol (uE3) and inhibin-A. MMS can identity Down syndrome (70% detection 
rate), Trisomy 18 (60% detection rate), spina bifida (80% detection rate), and anencephaly (90% 
detection rate)[1].   
While these prenatal screening tests are non-invasive, they are not diagnostic. These 
screenings also result in false positives. The false positive rate for Down syndrome detection is 
5% using FTS and 5.2% using MMS[2]. Combining these screening methods and performing 
them at multiple gestational ages, known as integrated screening, can lower the false positive rate 
to 1.9%[2]. These false positive results are a great source of anxiety for expectant parents. When 
a patient receives abnormal screening results, they are advised that a definitive diagnosis can 
only be given by chorionic villus sampling or amniocentesis.  
1.2 PRENATAL DIAGNOSTIC TESTS 
When prenatal genetic testing is warranted to confirm the presence or absence of a condition, the 
current standard of care for the patient is to undergo an invasive procedure, either chorionic 
villus sampling (CVS) or amniocentesis, to extract fetal DNA for further testing. Further testing 
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on the fetal sample may include karyotype analysis, fluorescence in situ hybridization (FISH) 
analysis, microarray analysis, and specific testing for certain monogenic disorders. CVS is 
generally performed between  10-13 weeks of gestation and amniocentesis is generally 
performed after 15 weeks gestation[3]. Because of the invasive nature of these tests there are 
risks associated with them for the patient and also to the fetus including a risk of miscarriage[4-
8]. While the risk of miscarriage may be low, 0.1% at experienced centers, this can lead to 
additional parental anxiety. Due to these risks, a less invasive, yet still definitive test is desired 
for fetal genomic testing.  
1.3 NON-INVASIVE PRENATAL DIAGNOSTIC TESTING FOR CHROMOSOMAL 
ABNORMALITIES 
It is well established that fetal cells are present in the maternal blood stream [9-12]. Fetal cells 
isolated from maternal blood have been used to test for aneuploidy and monogenic disorders [11, 
12]. However these cells are extremely rare and estimated to only be present at one fetal cell per 
milliliter of maternal blood[11]. Isolation of these cells is very difficult and clinical trials for 
aneuploidy testing via the isolation and analysis of fetal cells showed that the sensitivity was 
very similar to existing serum screening tests for Down syndrome due to the difficult nature of 
actually isolating fetal cells [13, 14].  
In 1997, Dennis Lo showed that fetal DNA is present as part of the circulating cell-free 
DNA in plasma and serum by detection of the Y chromosome in mothers of male fetuses[15]. 
Using a digital PCR method, it was shown that the median fetal-DNA concentration in the 
maternal plasma for the first, second, and third trimesters was 9.7%, 9.0%, and 20.4% 
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respectively[16]. In 2008, two groups demonstrated that it was possible to diagnose fetal 
aneuploidy from the maternal plasma using newly developed shotgun sequencing technology 
[17, 18]. Non-invasive prenatal detection of fetal aneuploidy has now become part of the regular 
clinical offering for women in their first trimester with commercial tests available such as 
MaterniT21 (Sequenom), Verifi (Progenity), Harmony (Ariosa), and Panorama (Natera).  
With the clinical success of aneuploidy testing using cell-free fetal DNA, the field is now 
looking to the detection of other fetal genetic anomalies such as deletions and duplications as 
well as resolving the entire fetal genome using cell-free DNA from the mother to enable 
diagnosis of Mendelian disorders.  
1.4 NON-INVASIVE PRENATAL DIAGNOSTIC TESTING FOR MONOGENIC 
DISORDERS 
The original discovery of the presence of cell-free DNA in maternal blood was based on the 
detection of sequence, the Y chromosome, not present in the maternal genome. These paternally 
inherited sequences, where the mother lacks the paternal allele, are readily detectable using 
standard PCR methods because no sequence specific maternal background exists. In this fashion, 
clinical tests are currently in use to detect fetal RHD status with cell-free DNA[19]. Detection of 
the paternal allele can be used to diagnose Mendelian disorders when the allele is autosomal 
dominant and can also be used to exclude when shown that the fetus did not receive the paternal 
allele, if different than the maternal, in an autosomal recessive disorder. This has been used for 
diseases such as Huntington’s, myotonic dystrophy, early onset primary dystonia, thalassemia, 
and achondroplasia [20-24].   
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In the case of an autosomal recessive disorder where the mother is a carrier and the father 
is also a carrier of the same allele, definitive diagnosis is much more difficult to make since the 
fetal DNA must be detected among the large background of maternal DNA with the same allele.  
 
 
Table 1: Expected allelic ratio change in plasma by fetal fraction. 
















As shown in to Table 1, when the mother and father are heterozygotes, the fetal genotype 
will be either: AB, AA, or BB. Since the cell free plasma DNA contains both mother and fetal 
DNA the allelic ratio in the plasma DNA will be skewed from 50/50 when the fetus is 
homozygous for one of the alleles. The degree to which that ratio will be different from 50/50 
depends on the fetal fraction. If the B allele represents the deleterious allele then anytime B 
counts are greater than A counts, the fetus inherited the deleterious allele. Plasma DNA is highly 
fragmented and is found at very low levels. In general, conventional methods to measure allele 
frequency such as Taqman SNP assays are not sensitive enough to be able to detect these minor 
allele ratio shifts. In 2008, Lun et al published two digital PCR based methods, Digital Relative 
Mutation Dosage (RMD) and Digital Nucleic Acid Size Selection (NASS) to detect these allelic 
ratio shifts for two mutations in the HBB gene for which the mother was heterozygous[25]. 
When used in tandem, they were only able to accurately classify 6 of 10 second trimester 
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maternal plasma samples[25]. Improved methods and droplet digital PCR machinery have made 
digital PCR a more viable option for diagnosis. In 2014, a study was published where this 
approach was used to diagnose whether a fetus had an autosomal recessive disorder, 
methylmalonic acidemia[26]. Although digital PCR has become increasingly more accessible, 
the technology still relies on single amplicon amplification such that multiple PCR reactions 
would be required to test for more than one disorder. Also, since cell free plasma DNA is found 
in such low quantities, the number of distinct tests that could be run on a single sample is limited. 
Ideally one test would be able to screen for multiple disorders with the same sample and all 
testing would be completed at one time.  
In 2012, two groups published papers showing that the entire fetal genome could be 
derived by molecular counting of the parental haplotypes within plasma DNA by shotgun 
sequencing [27, 28]. Instead of depending on counting the allelic ratio shift at one locus, they 
used the allelic ratio shifts at multiple nearby loci to detect which haplotype block the fetus 
inherited and thus are able to deduce whether the fetus inherited a specific allele. Lam et al also 
used parental haplotypes and shotgun sequencing to derive the fetal genome, but they chose to do 
it in a targeted manner[29]. By targeting parts of the genome instead of the entire genome, higher 
read depth is possible with fewer sequencing reads, decreasing costs and allows focus on 
clinically relevant loci. They targeted a 288Kb region of the HBB gene and were able to 
determine if the fetus inherited either mutation from the mother or the father[29]. Each of these 
approaches relied on first classifying the maternal haplotypes. The paternal haplotype is deduced 
from the presence of paternally inherited alleles, where the mother does not share the paternal 
allele, and are detectable after shotgun sequencing. The methods presented in these three papers 
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for determining the haplotypes for the mother are time and cost intensive. Therefore a more cost 
effective and less time intensive method is needed to haplotype the mother. 
Currently there are no non-invasive prenatal commercial tests available for the detection 
of monogenic disorders using either cell-free DNA or fetal cells from a maternal blood sample. 
There are tests available for many monogenic disorders which are used regularly in the clinical 
setting such as cystic fibrosis, sickle cell, thalassemia’s, and panels specific to disorders common 
in certain populations such as Ashkenazi Jews. These tests require pure genomic DNA so they 
can only be used to test parental samples and a pure fetal sample from a CVS or amniocenteses. 
The prevalence of monogenic disorders at birth is 10/1000 births[30]. The prevalence of 
monogenic disorders at birth is 10 times higher than the prevalence of Down syndrome, a now 
commonly screened for chromosome defect, which occurs in about 1:1000 live births[30]. 
Unlike Down syndrome there is no non-invasive prenatal test for these autosomal recessive 
monogenic disorders. A non-invasive prenatal test needs to be developed to detect autosomal 
recessive monogenic diseases. Cystic Fibrosis is the most common monogenic disorder 
worldwide and developing a non-invasive test to detect Cystic Fibrosis prenatally would yield a 
significant public health impact.  
1.5 CYSTIC FIBROSIS 
Cystic fibrosis of the pancreas, more commonly known as cystic fibrosis, is a life threatening 
progressive multi-system disorder. “Cystic fibrosis affects the epithelia of the respiratory tract, 
exocrine pancreas, intestine, male genital tract, hepatobiliary system, and exocrine sweat 
glands…”[31]. Mucus protects the linings of airways, digestive system, reproductive system, and 
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other organs and tissue, but in those affected with cystic fibrosis, the mucus produced is 
abnormally thick and sticky[32]. The disease shows great phenotypic heterogeneity. In the 
respiratory tract, the abnormal mucus can clog the airways leading to inflammation and chronic 
endobronchial infection, which leads to immune system failure in the lungs causing bacterial 
endobronchitis, which leads to further obstruction and inflammation[31].  Digestive problems are 
also seen with the majority of those affected having pancreatic insufficiency and less than 10% 
affected having pancreatic sufficiency[31]. “In people with cystic fibrosis, mucus blocks the 
ducts of the pancreas, reducing the production of insulin and preventing digestive enzymes from 
reaching the intestines to aid in digestion… a shortage of insulin can cause a form of diabetes 
known as cystic fibrosis-related diabetis mellitus.”[32]. Infertility due to azoospermia is seen in 
over 95% of males[31]. The leading cause of death is pulmonary disease and the second leading 
cause of death is liver disease[31]. Median survival is 36.5 years with greater survival in males 
and in those with pancreatic sufficiency[31]. 
Cystic fibrosis is caused by mutation in the cystic fibrosis transmembrane conductance 
regulator gene CFTR on chromosome 7. The CFTR gene codes for a protein channel responsible 
for transporting chloride ions which helps to control the movement of water in the tissues, 
necessary for the production of normal mucus[32]. Without enough water, this mucus becomes 
thick and sticky. Inheritance of cystic fibrosis is autosomal recessive. Two deleterious alleles are 
required and carriers of one allele do not show symptoms. Over 1900 mutations in the CFTR 
gene have been identified that might cause dysfunction of the CFTR protein [33]. Only a few 
dozen of those have been well classified for their impact on the CFTR protein [34]. These 
mutations can be classified into six main categories (I –VI) causing either complete absence of 
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protein to decreased stability of the membrane [33]. Figure 1 below summarizes the six 




Figure 1: Classes of CFTR mutations. 
CFTR mutations are classified into 6 categories. The delF508 mutation is class II. Reprinted from The Lancet 
Respiratory Medicine, Volume 1, Issue 2, Boyle, Michael P., De Boeck, Kris, A new era in the treatment of cystic 
fibrosis: correction of the underlying CFTR defect, Pages 158-163, Copyright 2013, with Permission from Elsevier.  
 
Cystic fibrosis is the most common fatal genetic disease in persons of northern European 
heritage[35]. It occurs in 1:3200 live births of northern European ancestry, 1:15000 in African-
Americans, and 1:31000 in Asians[35]. The risk of being a cystic fibrosis carrier is 1:29 (3.44%), 
1:28 (3.57%), and 1:61 (1.64%) in Ashkenazi Jews, North American of northern European 
heritage, and African-American respectively[36, 37]. Those in the at-risk population for cystic 
fibrosis are advised to have cystic fibrosis carrier screening by genetic counselors during 
pregnancy. If both parents are carriers, an invasive procedure may be performed to determine if 
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the fetus is affected.  The current cystic fibrosis mutation panel endorsed by the American 
College of Medical Genetics (ACMG) covers 23 mutations with frequencies over 0.1%, which 
account for roughly 84% of all the mutations in a pan-ethnic U.S. population[38]. Sosnay et al 
analyzed the phenotypes and penetrance of all variants at or above 0.01% in cystic fibrosis 
patients and found an additional 104 variants to be pathogenic [34]. They estimated that testing 
for all 127 variants accounted for 95.4% in their sample versus 87.5% by testing only the 23 
ACMG genes [34]. The carrier screening cannot actually provide a true negative result because 
of the limited markers that are tested. However, having a negative result on a carrier screening 
significantly decreases the patient’s chance of being a cystic fibrosis mutation carrier. Next 
generation sequencing technologies have an advantage because more mutations can be detected 
and one study indicated that using sequencing technologies for CFTR testing would increase 
mutation detection to 98.7%[39].  
The delF508 mutation is the most common CFTR mutation. Worldwide, roughly 90% of 
affected individuals have at least 1 copy of this mutation in conjunction with another mutation 
and 50% are homozygous for the mutation [33]. According to the ACMG, the delF508 mutation 
accounts for the highest percentage of CFTR mutations found in all but one of the US 
populations studied. Among US populations the frequency of the delF508 mutation is 72.42% in 
Non-Hispanic Caucasians, 54.38% in Hispanic-Caucasians, 44.07% in African-Americans, and 
31.41% in Ashkenazi Jews[38]. The delF508 mutation is a 3 base pair nucleotide deletion 
resulting in the loss of an amino acid, phenalynine, causing the resulting protein to misfold and 
not be trafficked to the cell-surface [33]. Studies on European populations revealed “… a clear-
cut north-west to south-east gradient of delF508 prevalence in CF patients showing a maximum 
prevalence of 88% in Denmark to a minimum of 24.5% in the Turkish population”[40]. It is 
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estimated that the delF508 mutation is at least 52,000 years old and may have arisen in the 
Baluchi population in the Middle East [40, 41].  
1.6 DESIGN CONSIDERATIONS 
1.6.1 Haplotyping Assay Design 
In order to reduce the cost of sequencing on a per sample basis, the haplotyping and plasma 
genotyping assay needs to be targeted to the disease allele region. Whole genome haplotyping is 
not necessary as the clinical question revolves around the fetus inheriting the delF508 mutation 
and nothing else. The size of the region needs to be long enough so that it contains enough loci to 
differentiate parental haplotypes, but not cover such a long span that would contain a site where 
a recombination event may occur. A meiotic recombination event is estimated to occur about 
once per chromosome arm per generation[42]. In order to minimize the chance of spanning a 
recombination site, the degree of linkage disequilibrium (LD) should be maximized across those 
loci. A region of high LD means that rather than alleles segregating completely independently, 
the alleles segregate as small blocks. The degree of LD between SNPs will also vary by 
population. In the CEU population (Utah residents with ancestry from northern and western 
Europe), the CFTR gene consists of 3 haplotype blocks, each outlined in black, spanning 108Kb, 
70Kb and 2Kb respectively[43]. The delF508 mutation is found within the first block. Since 
there is less of a chance that recombination will occur within the haplotype block, only SNPs 






Figure 2: LD Plot of the CFTR gene (Hapmap CEU Population) 
The CFTR gene consists of 3 haplotype blocks spanning 108Kb, 70Kb and 2Kb respectively[43]. 
 
Figure 3 outlines the method by which loci were targeted and connected for haplotyping. 
Within haplotype block 1, from Figure 2, 12 SNPs plus the delF508 mutation were targeted via 
long range PCR. SNPs were chosen based on their inclusion within the Hapmap database and 
those that possess a high heterozygosity rate (>40%) to maximize the genotype differences 
within the samples. Additionally, these loci had to be close enough together for long range PCR. 
These 13 sites span 35.5 Kb. In order to link heterozygous loci, it is necessary for each locus to 
link to multiple loci. In total 42 long range amplicons were designed to connect 13 loci. These 
long range amplicons were 269-14,296bp in length. While the Illumina sequencers are capable of 
up to 300bp paired-end sequencing, the total fragment length still poses a limitation for the on-
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board sequencing chemistry. Typical amplicon lengths for sequencing are 200-500bp, but 
amplicons up to 1500bp in size can be used. Since the majority of the long range amplicons 
exceed the optimum length, it is necessary to make the final amplicons smaller while still 
containing the two far away loci. Therefore, after long range amplification, the amplicons are 
circularized and an inverse PCR is performed on the circularized fragment. These new inverse 







Figure 3: Strategy for the haplotyping of nuclear DNA. 
Long range PCR was performed on each amplicon individually and per sample. Long range amplicons are 
circularized and then an inverse PCR is performed on the circularized products. 
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1.6.2 Plasma Genotyping 
To non-invasively haplotype the fetus using the parental haplotypes, allele counts need to be 
attained across the haplotyped loci. In order to obtain sufficient sequencing depth to calculate 
allele frequencies economically a targeted approach must be used to sequence the plasma DNA. 
Agilent SureSelect, which uses RNA baits, was used previously for this purpose[29]. However, 
custom panel designs have a high up front cost and are not economical for the small amount of 
loci that this parental haplotyping method was initially designed to cover. Multiplex PCR of 
plasma DNA is more economical for this purpose. However, since PCR results in exponential 
amplification rather than linear amplification, the allele frequency at heterozygous sites, in 
practice, is often skewed from 50/50 in a pure sample due to uneven amplification of alleles. 
This was discussed previously in section 1.4. The expected change in ratio in the plasma sample 
is very slight (Table 1) and the unequal amplification resulting from PCR will create noise, 
making the allele frequency change from the fetus potentially undetectable. Since amplification 
of the plasma DNA is necessary, a unique molecular identifier (UMI) is attached to the DNA 
prior to amplification. The UMI is a 12bp nucleotide sequence which tags each starting DNA 
molecule so that after amplification, PCR duplicates can be removed and only unique molecules 
are used for the allele counts.   A conventional PCR design could be used to target the loci, but 
would not allow individual tagging of each molecule prior to amplification. This method allows 





Figure 4: Strategy for genotyping plasma DNA. 
Custom adaptors containing a 12bp unique molecular identifier (UMI) were ligated onto plasma and used for library 
amplification. Amplification products were circularized and inverse PCR was performed to linearize the products for 
subsequent sequencing library preparation.  
1.7 PUBLIC HEALTH SIGNIFICANCE 
All states now test for cystic fibrosis as part of their newborn screening panel[44]. The test for 
cystic fibrosis as part of newborn screening is two-tiered (IRT+DNA) in most states including 
Pennsylvania[44]. The first part of the test measures the levels of immunoreactive trypsinogen 
(IRT). If the level of IRT is high and a two-tiered test is performed, DNA is extracted from the 
blood spot for CFTR mutation testing. If the state uses an IRT-Only method then a subsequent 
newborn screening test is performed a few weeks later. If the child still has an elevated IRT 
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level, then a sweat test will be performed for definitive diagnosis. Newborn screening accounted 
for 60% of newly detected cystic fibrosis cases[44]. The IRT test used in newborn screening has 
significant drawbacks. Studies have shown that IRT/DNA screening has a very high sensitivity 
and specificity, but the initial IRT testing is prone to false positives [45]. In a study from the 
Netherlands, 1,493 out of 145,499 (1%) newborns had a high IRT level. Further genetic testing 
was performed and only 37 of the newborns were affected with cystic fibrosis (67 were carriers) 
[45]. 93%.of the newborns screened with high IRT levels had no CFTR mutations detected [45]. 
Based on this study, out of 10,000 births, 100 newborns will have a high IRT level and be 
directed for further testing, but 93 of those 100 will be false positives. This high false positive 
rate is concerning due to the likely parental anxiety that would occur should parents be notified 
that their newborn might have a serious, life-limiting genetic condition while they wait for a 
definitive answer. 93 out of those 100 were caused additional unwarranted stress during an 
already stressful time.  
A definitive, one-time genetic based test for cystic fibrosis would likely be preferable to 
most parents rather than the current newborn based screening test with high initial false positive 
rates especially in states where DNA testing is not done by default. Additionally, performing this 
test prenatally would give parents additional time to consider their options. Currently, this testing 
is offered through invasive procedures (CVS and amniocentesis), but since these invasive 
procedures carry some risk to the fetus, this causes additional parental anxiety. A non-invasive 
prenatal test for cystic fibrosis would have little to no risk and also provide parents more time to 
make reproductive decisions.    
Increased prenatal screening for cystic fibrosis will also likely have a positive economic 
impact. Life expectancy has increased dramatically due to medical advancements in treatment 
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over the last few decades for those with cystic fibrosis, but these new treatments come at a high 
cost. A 2013 study found that the average cost of care for treating cystic fibrosis was $15,571 
annually [46]. The mean annual costs for mild, moderate, and severe disease are $10,151, 
$25,647, $33,691 respectively [46]. Certain mutation combinations in the CFTR gene are 
associated with increased severity of the disease. Earlier diagnosis for cystic fibrosis would give 
parents more time to identify clinical and psychosocial resources to facilitate their needs and 
decision-making processes.  For example, parents may decide to undergo pre-implantation 
genetic diagnosis procedures in the future, and this may lead to at least some decrease in the 
births of affected fetuses.  
 Proposed here is a method to haplotype genomic maternal and paternal samples to aid in 
the assignment of the fetal haplotype from sequencing maternal plasma cell-free DNA. 
Additionally, the incorporation of unique molecular identifiers (UMI) allows plasma reads 
resulting from PCR amplification to be removed so that only the original molecules are used in 
the allele frequency count. This assay is designed to haplotype the region in the CFTR gene 
containing the delF508 mutation. Cystic fibrosis is the most common monogenic disorder 
worldwide and the delF508 mutation is the most common mutation causing cystic fibrosis. 
Currently there are no commercially available non-invasive prenatal tests for cystic fibrosis or 
other autosomal recessive monogenic disorders. This design could be used to target other CFTR 
mutations as well as other loci linked to monogenic disorders.   
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2.0  SPECIFIC AIMS 
Specific Aim 1: To evaluate a new method to haplotype maternal and paternal samples of trios in 
the CFTR region.  
 
Specific Aim 2: To evaluate whether the delF508 mutation is likely associated with one or 
multiple haplotypes within this sample population.  
 
Specific Aim 3: To evaluate a new method to count allele frequency in plasma using a unique 
molecular identifier and assign the fetal haplotype.  
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3.0  METHODS 
Recruitment 
Samples from six families, containing paternal blood, maternal blood, and pure fetal sample were 
obtained and used for evaluation of the haplotyping method. Two of these families consist of 
paternal and maternal delF508 carriers with the fetus not inheriting the delF08 mutation in either 
family. Five of the six maternal samples came from patients who reported their ethnicity as white 
and one of the maternal samples reported themselves as multiple. Only one of the six paternal 
samples was reported as white and there was no data for the other five. Ethnicity is not reported 
for the fetus. Due to a limited number of available samples, use of only trios with reported 
ethnicity information was not practical. Since the delF508 mutation is most prevalent in the 
Caucasian population and a vast majority of patients seeking prenatal genetic testing at Magee-
Womens Hospital identify themselves as Caucasian,  the CEU population (Utah residents with 
ancestry from northern and western Europe) in the Hapmap database will be used for reference 
LD and haplotype information. The University of Pittsburgh Institutional Review Board 
approved the patient consenting process and collection of all samples used in this study. Written 
informed consent was obtained for every sample.  
DNA extraction 
Parental genomic DNA was extracted from frozen blood minus the plasma portion using the 
QIAmp DNA Blood Midi Kit (Qiagen) as per protocol. Fetal genomic DNA was extracted from 
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CVS or amniocyte cultures. Cells were dissociated from culture dishes by treating with 0.05% 
Trypsin with EDTA (Invitrogen) for 10 minutes at 37°C followed by dilution with 1ml of DPBS 
(Gibco). The cellular solution was centrifuged at 500 x g for 5 minutes at 4°C and supernatant 
was removed. The cell pellet was resuspended in 200µl DPBS (Gibco). DNA from cultured CVS 
or amniocytes was extracted using the QIAmp DNA Mini Kit (Qiagen) as per protocol. 
Extracted DNA was quantified by nanodrop.  
Haplotyping of Nuclear DNA 
Long range PCR was performed on each amplicon individually and per sample. Input DNA for 
parental samples was 5ng and 6ng for fetal samples per PCR. The PCR cycling conditions were 
1 minute at 98°C, 35 cycles of 98°C for 10 seconds, annealing for 30 seconds, extension at 72°C, 
and a final extension at 72°C for 5 minutes using Phusion HF Polymerase (Fisher Scientific). 
Annealing temperature and extension time varied per amplicon according to appendix Table 11. 
Long range amplicons were purified then treated with 2.5U T4 Polynucleotide Kinase (NEB) in 
1x T4 DNA Ligase Buffer at 37°C for 30 minutes. 100U T4 DNA Ligase (NEB) was added 
directly to the reaction which was incubated for 2 hours at 25°C for circularization of fragments. 
Ligation products were purified then amplified. PCR cycling conditions were 2 minutes at 98°C, 
35 cycles of 98°C for 10 seconds, annealing for 30 seconds, extension at 72°C for 30 seconds 
and a final extension at 72°C for 5 minutes. Annealing temperatures varied per amplicon 
according to Appendix Table 12. PCR products were purified. All purification steps were done 
using 1x volume of AmpureXP Beads (Beckman Coulter) with 80% ethanol washes. A portion 
of each final PCR product was run on a gel to confirm amplification of the correct product and to 
estimate relative concentrations. Per sample, each PCR product was combined based on relative 
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concentrations. Pooled PCR products were gel purified, cutting fragments 100-400bp. Min-Elute 
Gel Extraction Kit (Qiagen) was used for cleanup.  
Sequencing Library Preparation 
Gel purified PCR products were quantified using the 2100 Bioanalyzer (Agilent) and 81-300ng 
of pooled products were used as input for library prep. Amplicon libraries were prepared using 
NEBNext Ultra Library Prep Kit as per protocol except Illumina TruSeq Indexed Adaptors were 
used during adaptor ligation and final libraries were amplified 12 cycles using Phusion HF 
Polymerase (Fisher Scientific) and custom primers: forward 5’-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGA-3’ and reverse 5’-
CAAGCAGAAGACGGCATACGAGAT-3’. Libraries were quantified via real time PCR and 
via bioanalyzer (Agilent).  
Genotyping of Plasma DNA 
Plasma was separated from whole blood via centrifugation at 1,600 x g for 10 minutes, followed 
by a second centrifugation to remove contaminating nucleated cells at 16,000 x g for 10 minutes.  
DNA was extracted from 3.6ml of plasma using the QIAamp DNA Blood Mini kit (Qiagen) as 
per protocol. Amplicon libraries were prepared using NEBNext Ultra Library Prep Kit as per 
protocol except custom adaptors were used during adaptor ligation. An equimolar mixture of 
AGCCGCCTTTCCATAGTGAGTCCTTCGTCTGTGACTAACTGTGCCAAATCGTCTAGC
AA*T (* = phosphorothiate bond) and 5' phos-
TTGCTAGACGATCAATTTGACCTANNNNNNNNNNNNAGTCGACGGTTAGAACCTAG
GGTC oligos were combined and heated for 5 minutes at 95°C then were slowly cooled to room 
temperature. Final adaptor concentration in ligation mixture was 5nM. Libraries were amplified 
12 cycles using Phusion HF Polymerase (Fisher Scientific) and custom primers: forward 5’- 
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AGCCGCCTTTCCATAGTGAGTCCTTCGT-3’ and reverse 5’- 
GACCCTAGGTTCTAACCGTCGACT-3’. Amplified libraries were purified then treated with 
2.5U T4 Polynucleotide Kinase (NEB) in 1x T4 DNA Ligase Buffer at 37°C for 30 minutes. 
400U T4 DNA Ligase (NEB) was added directly to the reaction which was incubated for 2 hours 
at 25°C for circularization of fragments. Ligation products were purified then amplified. Inverse 
PCR primers for each of 24 loci were combined in equimolar ratios and final total primer 
concentration was 12µM in the PCR. Sequences for plasma inverse PCR primers are located in 
Appendix Table 13. PCR cycling conditions were 2 minutes at 98°C, 35 cycles of 98°C for 10 
seconds, 60°C for 30 seconds, extension at 72°C for 30 seconds and a final extension at 72°C for 
5 minutes. PCR products were purified. Libraries were prepared for sequencing according to 
“Sequencing Library Preparation” protocol stated previously. All purification steps were done 
using 1x volume of AmpureXP Beads (Beckman Coulter) with 80% ethanol washes. 
Sequencing and Bioinformatics 
All libraries were sequenced using an Illumina Miseq with 150bp paired-end reads. Reads for 
haplotyping were quality and adaptor trimmed using TrimGalore[47]. Reads were trimmed to 
75bp in order to remove the junction point of the adjoining ends of the long-range PCR amplicon 
using the Fastx Toolkit [48]. Reads were aligned in single-end mode to a custom fasta reference 
file containing only the amplicons of interest using Bowtie and allowing no mismatches and 
keeping only uniquely mapped reads[49]. Aligning with no mismatches allowed for exact 
assignment of the allele and only uniquely mapped reads would contain the allele because both 
sequences, which only varied at the mutation, were present in the fasta reference file. Single end 




25ng of fetal DNA were used for each PCR reaction. The PCR cycling conditions were 30 
seconds at 98°C, 35 cycles of 98°C for 10 seconds, annealing for 30 seconds, extension at 72°C, 
and a final extension at 72°C for 5 minutes using Phusion HF Polymerase (Fisher Scientific). 
Annealing temperature varied per amplicon according to Appendix Table 15. Products were gel 
purified using MinElute Gel Extraction Kit (Qiagen).  
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4.0  RESULTS 
4.1 SPECIFIC AIM 1 
 
13 SNPs were chosen for haplotyping and a total of 42 amplicons were designed to inter-connect 
the SNPs. Each long range PCR and inverse PCR reaction was optimized for annealing 





Figure 5: Example long range and inverse PCR annealing profile. 
Example long range and inverse PCR annealing profile. PCR annealing profile of A) long-range PCR amplicon 
(7401bp) and B) corresponding inverse PCR amplicons 194bp). M = 100bp DNA ladder. Lanes 2-7 contain PCR 
reactions run at increasingly higher annealing temperatures.   
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Six trios consisting of maternal, paternal and fetal genomic DNA were sequenced on an 
Illumina Miseq with 150bp paired-end reads. After trimming, alignment and read merging an 
average of 342,651 pairs (41.13%) per sample were kept for further analysis. Detailed 
sequencing statistics can be found in Appendix Table 16. The average depth at each SNP site 
varied (Table 3) drastically, from 196X-122,159X, due to PCR amplification efficiency and the 
number of amplicons that were designed to cover a particular SNP.  Exact concentrations were 
not calculated, because of cost and time, for each amplicon prior to pooling so it was expected 
that the reads for each amplicon would vary. Additionally, some SNPs had more amplicons 
covering them because of limitations of the surrounding genomic sequence for PCR design. 
SNPs rs2082056, rs213965, and rs213971 had the lowest average depths at 196X, 214X, and 
1040X respectively. The low depths at these 3 SNPs indicate a very poor PCR efficiency of the 
amplicons covering those SNPs versus the PCR efficiencies of the 10 others. Further 
optimization would be needed to either redesign these amplicons or to remove those SNPs from 
the design and choose others.  All SNPs still contained enough depth to determine genotype and 



















Table 2: Sample information. 
Trio 
Number 
Sample Name Sample Type delF508 status Reported Ethnicity 
1 G1342 Maternal blood Non-carrier White 
G1343 Paternal blood Non-carrier  
12-032 CVS Cultured CVS Non-carrier  
2 G1687 Paternal blood Carrier  
G1688 Maternal blood Carrier White 
13-014 Cultured amnio carrier  
3 G1700 Maternal blood Carrier Multiple 
G1701 Paternal blood Carrier  
13-019 Cultured amnio Non-carrier  
4 G1747 Maternal blood Non-carrier White 
G1748 Paternal blood Non-carrier White 
13-049 CVS Cultured CVS Non-carrier  
5 G1831 Maternal blood Non-carrier White 
G1832 Paternal blood Non-carrier  
13-089 CVS Cultured CVS Non-carrier  
6 G1841 Maternal blood Non-carrier White 
G1842 Paternal blood Non-carrier  
13-093 CVS Cultured CVS Non-carrier  
 
 
Table 3: Read depth at targeted sites. 





to Cover SNP 
rs213950 G/A 122,159 5 
rs113993960 CTT/- 60,604 5 
rs1896887 G/C 55,262 5 
rs718829 C/A 107,084 7 
rs2082056 T/C 196 8 
rs213934 T/C 115,637 9 
rs2518873 C/T 19,302 7 
rs213955 A/G 31,458 8 
rs6949974 C/T 36,024 8 
rs17547853 G/A 65,762 7 
rs213965 T/A 214 6 
rs213971 G/A 1,040 5 
rs1042077 T/G 66,677 4 
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Genotypes were assigned based on allele frequencies of the properly aligned reads. 
Assigned genotypes for each sample can be found in Tables 4-6. Detailed allele counts for each 
sample can be found in Appendix Table 17. The genotypes of each of the fetal samples were 
consistent with the genotypes of the parents in every case. The genotype at the delF508 mutation 
(rs113993960) was also consistent with the clinical data received from each patient. Sites that 
were homozygous in each sample could be linked as part of a haplotype. For example, G1343 is 
homozygous at all sites genotyped so the haplotype can be assigned (see Table 8) without any 
further analysis.  
 
Table 4: Assigned genotypes in trios 1 and 2. 
 Trio 1 Trio 2 
G1342 G1343 12-032 G1688 G1687 13-014 
rs213950 G/A a/a g/g g/a g/a g/a g/a 
rs113993960 CTT/- ctt/ctt ctt/ctt ctt/ctt ctt/- ctt/- ctt/- 
rs1896887 G/C g/c g/g g/g g/g g/g g/g 
rs718829 C/A a/a c/c c/a c/a c/a c/a 
rs2082056 T/C c/c t/t t/c t/c t/c t/c 
rs213934 T/C c/c t/t t/c t/c t/c t/c 
rs2518873 C/T t/t c/c c/t c/c  c/c c/c 
rs213955 A/G g/g a/a a/g a/g a/g a/g 
rs6949974 C/T c/t c/c c/t c/c  c/c c/c 
rs17547853 G/A g/g g/g g/g g/g g/g g/g 
rs213965 T/A a/a t/t t/a t/a t/a t/a 
rs213971 G/A a/a g/g g/a g/a g/a g/a 






Table 5: Assigned genotypes in trios 3 and 4. 
 Trio 3 Trio 4 
G1700 G1701 13-019 G1747 G1748 13-049 
rs213950 G/A g/a g/a g/g g/a g/a g/a 
rs113993960 CTT/- ctt/- ctt/- ctt/ctt ctt/ctt ctt/ctt ctt/ctt 
rs1896887 G/C g/g g/g g/g g/g g/g g/g 
rs718829 C/A c/a c/a c/c c/a c/a c/a 
rs2082056 T/C t/c t/c t/t t/c t/c t/c 
rs213934 T/C t/c t/c t/t t/c t/c t/c 
rs2518873 C/T c/c c/c c/c c/t c/t c/t 
rs213955 A/G a/g a/g a/a a/a a/a a/a 
rs6949974 C/T c/c c/c c/c c/t c/t c/t 
rs17547853 G/A g/g g/g g/g g/g g/a g/a 
rs213965 T/A t/a t/a t/t t/a t/a t/a 
rs213971 G/A g/a g/a g/g g/a g/a g/a 
rs1042077 T/G t/t t/t t/t t/g t/g t/g 
 
 
Table 6: Assigned genotypes in trios 5 and 6. 
 Trio 5 Trio 6 
G1831 G1832 13-089 G1841 G1842 13-093 
rs213950 G/A g/a g/a g/a a/a a/a a/a 
rs113993960 CTT/- ctt/ctt ctt/ctt ctt/ctt ctt/ctt ctt/ctt ctt/ctt 
rs1896887 G/C g/g g/g g/g g/g g/g g/g 
rs718829 C/A c/a c/a c/a a/a a/a a/a 
rs2082056 T/C t/c t/c t/c c/c c/c c/c 
rs213934 T/C t/c t/c t/c c/c c/c c/c 
rs2518873 C/T c/t c/t c/t t/t t/t t/t 
rs213955 A/G a/a a/g a/a a/a a/g a/a 
rs6949974 C/T c/t c/t c/t t/t t/t t/t 
rs17547853 G/A g/g g/g g/g a/a g/a a/a 
rs213965 T/A t/a t/a t/a a/a a/a a/a 
rs213971 G/A g/a g/a g/a a/a a/a a/a 





Within each trio, counts were assigned to each possible combination of heterozygous 
loci. Table 7 shows the counts for trio 4 at the sites that were heterozygous. There are 4 possible 
categories for 2 heterozygous loci: ref-ref, ref-alt, alt-ref, alt-alt. However, only 2 combinations 
are biologically possible: 1) ref-ref/alt-alt or 2) ref-alt/alt-ref. What the counts consistently 
showed across all samples was that almost all 4 categories were present, meaning that the 
reference allele at one site was associated with both the reference and the alternate allele at the 
adjoining site. For example in sample G1747 between SNPs rs213950 and rs718829 there was a 
total of 46,414 counts. The expectation would be that close to 100% of the counts would be split 
relatively evenly in the ref-ref and alt-alt category with very close to 0% being in the opposite 
categories or vice versa with the counts in the ref-alt and alt-ref categories. Instead the data is 
showing that the reference allele for SNP rs213950 is associating with the reference allele 
rs718829 33.44% of the time, but is also associating with the rs718829 alternate allele 22.92% of 
the time. Similar results are seen for the alternate allele of rs213950 and rs718829.With few 
exceptions, all amplicons showed this result and were inconclusive. There were very few 
instances where the counts appeared to favor a particular SNP pairing. For example in sample 
G1747 between SNPs rs213950 and rs213934 the counts favored a pairing of rs213950 reference 
with rs213934 reference and a pairing of the alternate alleles. 42.63% of the time rs213950 
reference associated with rs213934 reference and the alternate alleles associated with each other 
44.34% of the time. These values are much closer to the expected 50% distribution between 
categories. Given that almost every other amplicon showed inconclusive results, this “positive” 
result is most likely just random and should not be used to construct the haplotype. Counts from 
the remaining trios can be found in Appendix Tables 18-22.  
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Table 7: Haplotype category counts at heterozygous loci for trio 4. 
SNP Pair 
Category 











rs213950_rs718829 ref-ref 15520 33.44% 17317 36.15% 8834 27.80% 
  ref-alt 10640 22.92% 10802 22.55% 7559 23.79% 
  alt-ref 10335 22.27% 10509 21.94% 7199 22.65% 
  alt-alt 9919 21.37% 9272 19.36% 8186 25.76% 
rs213950_rs213934 ref-ref 17166 42.63% 3381 23.00% 2048 27.76% 
  ref-alt 2807 6.97% 4650 31.63% 2192 29.71% 
  alt-ref 2439 6.06% 2532 17.22% 1336 18.11% 
  alt-alt 17856 44.34% 4138 28.15% 1801 24.41% 
rs718829_rs213934 ref-ref 6108 25.57% 4369 24.84% 11213 28.05% 
  ref-alt 6440 26.96% 5180 29.45% 11613 29.05% 
  alt-ref 5171 21.65% 3645 20.72% 8321 20.82% 
  alt-alt 6164 25.81% 4396 24.99% 8827 22.08% 
rs718829_rs2518873 ref-ref 1228 30.76% 363 29.42% 1971 31.36% 
  ref-alt 625 15.66% 209 16.94% 1071 17.04% 
  alt-ref 1454 36.42% 392 31.77% 2058 32.74% 
  alt-alt 685 17.16% 270 21.88% 1185 18.85% 
rs2082056_rs213934 ref-ref 
sample homozygous 
15 13.76% 28 21.21% 
  ref-alt 11 10.09% 17 12.88% 
  alt-ref 38 34.86% 43 32.58% 
  alt-alt 45 41.28% 44 33.33% 
rs213934_rs2518873 ref-ref 2260 36.45% 2250 31.84% 2690 37.42% 
  ref-alt 911 14.69% 1043 14.76% 1159 16.12% 
  alt-ref 2088 33.67% 2512 35.55% 2188 30.44% 
  alt-alt 942 15.19% 1262 17.86% 1152 16.02% 
rs213934_rs17547853 ref-ref 
sample homozygous 
1785 23.61% 3261 66.73% 
  ref-alt 1063 14.06% 165 3.38% 
  alt-ref 1565 20.70% 252 5.16% 
  alt-alt 3146 41.62% 1209 24.74% 
rs2518873_rs17547853 ref-ref 
sample homozygous 
643 46.09% 463 47.20% 
  ref-alt 358 25.66% 224 22.83% 
  alt-ref 188 13.48% 156 15.90% 
  alt-alt 206 14.77% 138 14.07% 
rs6949974_rs17547853 ref-ref 
sample homozygous 
2414 29.21% 2039 33.28% 
  ref-alt 1919 23.22% 1412 23.05% 
  alt-ref 2230 26.98% 1549 25.28% 
  alt-alt 1702 20.59% 1127 18.39% 

















7631 32.48% 9023 43.60% 
  ref-alt 4143 17.64% 4379 21.16% 
  alt-ref 4401 18.73% 4594 22.20% 
  alt-alt 7317 31.15% 2701 13.05% 
rs17547853_rs213971 ref-ref 
sample homozygous 
66 41.51% 35 39.33% 
  ref-alt 41 25.79% 28 31.46% 
  alt-ref 27 16.98% 13 14.61% 
  alt-alt 25 15.72% 13 14.61% 
rs17547853_rs1042077 ref-ref 
sample homozygous 
1286 20.78% 2234 27.18% 
  ref-alt 1410 22.78% 2720 33.09% 
  alt-ref 1019 16.46% 1509 18.36% 
  alt-alt 2474 39.97% 1756 21.37% 
rs213971_rs1042077 ref-ref 
sample homozygous 
147 32.67% 70 31.25% 
  ref-alt 126 28.00% 60 26.79% 
  alt-ref 83 18.44% 43 19.20% 
  alt-alt 94 20.89% 51 22.77% 
 
Each row shows the 2 linked loci and the counts associated connecting the reference or alternate alleles at each 
locus. If the 2 linked loci are homozygous at either linked site then counts are not given and “sample homozygous” 
is indicated.  
 
 
The haplotyping method proposed did not produce conclusive results to link 
heterozygous loci for a complete haplotype. However, using the homozygous alleles and the 
assumed inheritance within the trios, 3 of the 6 trios could be completely haplotyped across the 
13 loci. Table 8 shows the haplotypes determined.   In table 8, each column represents 1 of the 
13 targeted loci. Each row corresponds to a haplotype for a given sample with each sample 
having two haplotypes. The reference allele for rs113993960 (delF508) is “ctt” while the 
alternate (mutation) allele is the deletion of “ctt” denoted as “-“. For example, paternal sample 
G1343 of trio 1 was homozygous at all the loci meaning he has 2 copies of the same haplotype. 
G1343 is not a carrier for the delF508 mutation. Homozygous sites for sample G1342 and       
12-032 are also filled in with lower case letters. It is expected that the fetus would inherit one 
Table 7 (continued) 
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haplotype from the mother and one from the father. Since the paternal sample haplotype is 
known, 1 of the fetal haplotypes can be assumed and those sites are filled in with bold 
capitalized letters. The sites remaining in sample 12-032 are heterozygous, so whatever allele 
was not part of the paternal haplotype is part of the inherited maternal haplotype. Both fetal 
haplotypes are known and the maternal haplotypes in G1342 can be deduced based on the 
haplotype that the fetus inherited. Similar logic was followed to haplotype trios 3 and 6 starting 
with the completely homozygous sample within each trio. Trios 2, 4, and 5 could not be 
completely haplotyped due to the failure of the method to conclusively link heterozygous sites 
and the lack of homozygous sites to assume inheritance.  
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a ctt g a c c t A t A a a g 
a ctt g a c c t G t G a a g 
13-093 
 
a ctt g a c c t a t a a a g 
a ctt g a c c t a t a a a g 
 
Assigned haplotypes. The row names represent the 2 haplotypes for each sample and the column names are the loci.  
Homozygous sites are filled in by sample in lower case letters. Bold Capitalized letters represent heterozygous sites 
that could be phased due to inheritance. 
Table 8 (continued) 
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4.2 SPECIFIC AIM 2 
 
The targeted loci are all located within the first 108 Kb haplotype block in Figure 2 of the CFTR 
gene. Figure 6 shows a 38Kb sub-region of haplotype block 1. Within this sub-region there are 2 
blocks, denoted 1A and 1B, of linkage disequilibrium (LD). The alleles in block 1A are more 
likely to be inherited together and the alleles in 1B are also more likely to be inherited together. 
If a recombination event were to happen within this sub-region, the most likely location would 
be between blocks 1A and 1B which splits SNPs 13 and 15 into 2 separate blocks of LD. This 
assay only included SNPs 3, 4, 8, 12, 13, 17, 18 from Figure 6 so the other SNPs are blacked out. 
Based on the order of haplotypes in Figure 6, a number (1-15) was arbitrarily assigned to each 
haplotype. In Figure 6, the lines between the blocks represent the most likely continuous 
haplotype with the weight of the line indicating the most frequent combination of the 2 blocks if 
more than 1 is observed. Where there is no line, such as for haplotypes 6-15, no information was 
provided from Hapmap. For example the most likely continuous haplotype for haplotype 1 
across the blocks would be G/G/T/G/T/G/T. Any haplotype that could not be distinguished from 
the SNPs chosen in this assay are noted by connecting arrows. For instance, based on the 5 SNPs 
in block 1A, haplotypes 2 and 15 could not be distinguished from one another and it is marked 




Figure 6: CEU haplotypes in a 38Kb sub-region of CFTR. 
SNPs not targeted in this assay are blacked out. Each haplotype in block 1A is given a number 1-15. 




Each column of Table 9 shows the SNP and its corresponding Hapmap number (see 
Figure 6). 5 of the 13 SNPs targeted by this assay were not in Hapmap while 8 of the 13 were. 
The SNPs that weren’t in Hapmap are placed in order. For instance, the delF508 mutation 
(rs113993960) falls between SNPs 3 and 4. Each row of Table 9 shows the haplotype (1-15) 
from Figure 6. Because of the ambiguity of the continuous haplotypes between block 1A and 
block 1B of Figure 6 for all 15 haplotypes, SNPs 17 and 18, rs213971 and rs1042077 
respectively, are not included. The resulting haplotypes were compared to the known haplotypes 
from the CEU population in Hapmap and the loci not in Hapmap were assigned to specific 
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haplotypes. In Table 9, the last column on the right shows the number of times this haplotype 
was seen in the 18 samples in this data set. For instance, haplotype 1 was observed 7 times. 
 










































































2/15 A  G   C  A  A A 5x 
5 A  G   C  A  G A  
12 A ctt G a c C t G t G A 3x 
12a A - G a c C c G c G A 2x 
8 A  G   T  A  G T  
3/4/ 13 A  C   C  G  G A 1x 
10 A  C   C  G  G T  
7 A  C   T  A  G T  
1 G ctt G c t T c A c G T 7x 
6 G  G   T  A  G A  
14 G  G   T  A  A A  
9 G  G   C  A  G T  
11 G  G   C  A  G A  
 
Table is derived from Figure 6 and includes the SNPs that were covered in the assay. Numbers in parenthesis across 
the top reflect the SNP number from Figure 6 that was given in Hapmap. The observed column shows how many 
times this haplotype was seen in our data set. Alleles between the Hapmap SNPs covered in our assay are filled in to 




As seen in Table 9, two distinct versions of haplotype 12 were seen in our data set. These 
varied at 2 SNP sites that were not part of the Hapmap data. Two unrelated individuals, G1700 
and G1701, are delF08 carriers and the haplotype that the mutation corresponds to in the 
Hapmap data is haplotype 12. However, two other unrelated individuals, G1342 and G1842, also 
have haplotypes that correspond to haplotype 12. They are not delF508 carriers. There is a 
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subtype of haplotype 12 that carries the delF508 mutation. The mutation carrying version of 
haplotype 12 will be called 12a.  
Two fetal samples that are homozygous for the delF508 mutation were sanger sequenced 
at 12 of the 13 sites. The delF508 site was not sequenced in these samples as clinical testing 
already confirmed the deletion.  Both fetal samples were homozygous for the same haplotype. 
This haplotype corresponds with haplotypes 3/4/13 from Table 9. It is identical to one of the 
haplotypes found in sample G1342 except at the delF508 site where G1342 does not carry the 
delF508 mutation.  
 











































































11-067 A - C A C C T G C G A A T 








4.3 SPECIFIC AIM 3 
 
Two libraries were made from 3.6ml of plasma each. Plasma samples were not related to the 
trios. Products from plasma were checked throughout the preparation to confirm that the protocol 
was working as intended. Figure 7A shows the plasma DNA post-ligation with custom adaptors 
with a unique molecular identifier after amplification. After circularization, targeted 
amplification was performed via a multiplex inverse PCR (Figure7B). The resulting 
circularization products are various sizes due to the random fragmentation of plasma DNA. The 
products from the inverse PCR are also random because the SNP can fall anywhere within the 
circle. After inverse PCR, Illumina compatible adaptors were ligated to the products and the 
library was amplified. The addition of the final adaptors adds 120bp to the fragment. A fragment 
















Paired end reads generated for the 2 plasma libraries were 926,819 and 1,149,907. 
Further bioinformatics analysis is ongoing and nothing further can be presented to evaluate this 
method for counting allele frequency in plasma DNA. 
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5.0  DISCUSSION 
The aim of this project was to develop a new method for haplotyping pure paternal and maternal 
samples to aid in the assignment of the fetal haplotype after sequencing the maternal plasma 
DNA. 
Six trios comprising maternal, paternal, and fetal genomic DNA underwent a novel 
library preparation method and were sequenced in order to haplotype a 35.5Kb region of the 
CFTR gene which includes the delF508 mutation. All genotyping results within the trios were 
consistent with presumed inheritance among the trios. After analyzing the counts reflecting the 
linkage of the loci, it is clear that the method did not perform as intended. The counts showed 
that between 2 heterozygous sites, any given allele at one site was associated with both of the 
alleles at the linked site; a biological impossibility. One distinct possibility that would lead to 
these results is if prior to circularization, individual long range amplicons ligated to each other 
forming a concatemer. The resulting PCR product from the inverse PCR of a concatemer is the 
same size as the PCR product from the proper intra-molecular ligation. Figure 8 outlines the 






Figure 8: Formation of inverse PCR products not reflecting original linked loci. 
 
 
In order for this approach to work for haplotyping, it is necessary to minimize or 
completely remove the possibility of intermolecular ligation prior to circularization. Ligation by 
T4 DNA ligase can result in both inter and intra molecule ligation. Dugaiczyk et al showed that 
this was dependent on the effective concentration of one end of the DNA molecule to the other 
(j) and the effective DNA concentration(i)[50]. At a j:i ratio of 2 or higher, circular products 
were favored[50]. They proposed that the most effective way to promote circularization was to 
minimize i and lower the DNA concentration[50]. Since this method also relies on a range of 
long range amplicon sizes, this j:i ratio would be different for each as the length of DNA is 
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factored into variable j so potentially each reaction would have to be optimized separately[50]. 
Shoaib et al also found that low DNA concentrations led to self-circularization[51]. In their 
experiments, with concentrations of less than 1ng/ul, self-circularization was favored[51].  I also 
observed that intermolecular ligation was enhanced by increased concentrations of divalent 
cations[52]. T4 DNA ligase buffer contains the divalent cation MgCl2. Possibly decreasing the 
concentration of MgCl2 could limit the amount of intermolecular ligation.  
A better approach would be to remove the chance of formation of concatemers from the 
reaction. This could be achieved by physically separating the long range amplicons prior to 
ligation so that only 1 molecule is present. Similar to digital PCR workflows, the long range 
amplicons would be diluted to a point where only one molecule would be placed in a well on a 
plate. However, this approach would add significant time and cost to the protocol. Another 
option may be to use emulsions. An individual molecule, in this case the long range PCR 
amplicon, would be put into an individual droplet. This is very similar to current technology in 
droplet digital PCR machines except that instead of performing a PCR within the droplet, the 
ligation reaction would occur. At the present time, this is not technically feasible and would 
likely require very specific machinery to perform.     
From the homozygous loci and assumed inheritance within the trios, 3 of the 6 trios could 
be haplotyped across all 13 loci. All of the assigned haplotypes were consistent with at least one 
of the haplotypes seen in the Hapmap CEU population (Figure 6). Trio 3 was the only 
completely haplotyped trio that contained samples who were delF508 mutation carriers. The 
maternal (G1700) and paternal (G1701) samples were carriers for the delF508 mutation and the 
CEU haplotype that was consistent with the observed haplotypes was 12. However, a haplotype 
that was consistent with haplotype 12 was also seen in trio 1, samples G1342 and 12-032. When 
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the number 12 haplotypes are compared between trios 1 and 3 they vary at two sites: rs2518873 
and rs6949974. The version of haplotype 12 containing the delF508 mutation will be denoted as 
12a and the non-deletion version will be denoted as 12. Since two unrelated individuals carried 
the delF508 mutation on 12a, I wanted to explore if this was also the haplotype carried by two 
delF508 homozygotes. Sanger sequencing was performed on 2 cultured amniocyte DNA 
samples, 11-067 and 12-243 to genotype the 12 SNPs surrounding the delF508 mutation. Both of 
these samples were homozygous for the same haplotype. Instead of matching the previous 
haplotype 12a, they both carried a haplotype that was identical to one carried by G1342 which 
was consistent with CEU haplotype 3, 4, or 13. Due to the SNPs chosen, the haplotypes 3, 4 and 
13 could not be distinguished from one another.  This means that the delF508 mutation could 
occur on 3, 4 or 13. Further genotyping at sites not originally covered in this assay, but within 
Hapmap, on samples in the 3/4/13 haplotype category could be done in order to elucidate if any 
one of these three might harbor the delF508 mutation.  The results here indicate that the delF508 
mutation can be found on at least 2 haplotypes and is not associated with just one haplotype.  
In 2015, Zeevi et al published a study which they used consensus haplotype-mediated 
NIPD to non-invasively detect the N370S mutation causing Gaucher disease in the Ashkenanazi 
Jewish population in plasma [53]. They used next generation sequencing to perform 
homozygosity mapping around the GBA gene for 7 unrelated individuals who were homozygous 
for the N370S mutation [53]. Using the consensus sequence of homozygous unrelated 
individuals would remove the requirement for haplotyping the parents because a universal 
haplotype containing the mutation would be used. This would save significant time and cost. For 
delF508 detection, this approach would require finding the haplotype(s) associated with the 
deletion. In the N370S study, they were able to identify one founder haplotype carrying the 
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mutation among the homozygous individuals [53]. From this small delF508 experiment it is clear 
that at least 2 haplotypes are associated with the mutation and not just one. The N370S mutation 
is a young mutation compared to the delF508 mutation. The N370S mutation in the Ashkenazi 
Jewish population is estimated to be about 1000 years old or less whereas the delF508mutation is 
at least 52,000 years old[54]. With so many generations, it is likely that the delF508 mutation is 
associated with many more haplotypes than the N370S mutation. It would be feasible to perform 
homozygosity mapping on homozygous delF508 individuals, but a larger sample size would be 
needed to detect the likely multiple haplotypes containing the delF508 mutation. This same 
homozygosity mapping would also be required across multiple worldwide populations for 
validation that the test could be applied universally. 
While the method presented here would detect and utilize the paternal haplotype, it is not 
actually necessary to haplotype pure paternal DNA. It has been shown that the paternal 
haplotype can be deduced computationally from the sequencing of the plasma which contains the 
paternally inherited haplotype[27]. Not having to haplotype pure paternal DNA would save on 
time and cost, but is also important because the incidence of non-paternity is estimated to be 
between 3% and 10%[27]. 
The use of unique molecular identifiers in plasma DNA sequencing has the potential to 
negate the requirement for parental haplotypes. By individually tagging molecules prior to 
amplification, the allele frequency of only the “original” molecules can be counted rather than 
counting all of the PCR copies. Not taking into account the PCR copies may significantly reduce 
the noise enough that a very slight allelic ratio change could be detected. Analysis is ongoing for 
that part of this study.  
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For now, it appears that maternal haplotyping will be necessary to diagnose recessive 
monogenic disorders in the fetus. The proposed genomic haplotyping method described here is 
too time and labor intensive for everyday clinical use. Modification of the method to minimize or 
reduce the potential formation of concatemers may result in a workflow that would be more 
expensive and also take more time with the technologies available today. Additionally, this 
design only covered 35.5Kb and increasing the bases targeted to other monogenic disorder genes 
would need to involve multiplex PCRs that require loads of optimization. The consensus 
haplotype mediated method is probably not ideal due to the amount of testing across populations 
that would be required to validate it for just 1 mutation site.  
The most promising method moving forward for haplotyping parental genomic DNA 
would be to utilize longer sequencing reads. The longer the sequence, the more SNPs it will 
contain to form a haplotype. If the reads are long enough and contain multiple SNPs, complete 
de novo assembly of the haplotype is possible. Yang et al designed an algorithm called HARSH 
(Haplotyping with Reference and Sequencing technology) for haplotype phasing which uses a 
probabilistic model to incorporate the SNP information from the sequencing reads as well as a 
provided reference panel of haplotypes[55]. To test their algorithm, they simulated sequencing 
data of 100bp paired-end reads on 1000-4000bp fragments at 1X-10X sequencing coverage[55]. 
Using their algorithm, they were able to get as accurate results from 100bp paired end reads on 
1000bp fragments as they could from 100bp paired end reads on 4000bp fragments de novo 
assembled[55]. A 4000bp fragment is currently not sequenceable on the Illumina platform, but a 
1000bp fragment is. Moving forward with this experiment, a targeted sequencing method using 
100bp paired end reads on 1000bp fragments is the next logical step. Briefly, a targeting method, 
such as Agilent SureSelect, would be used to capture long fragments in the CFTR region. A 
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custom targeting panel does have high up-front costs, but the sample reagents could potentially 
be used on the plasma cell-free DNA for targeted sequencing of the same area. Unlike the 
method proposed here which targets 1 mutation in 1 gene, a targeting panel could be designed to 
easily cover many genes linked to monogenic disorders and any mutation within that gene.   
Another promising technology for long range haplotyping of genomic DNA is the SMRT 
(Single Molecule, Real-Time) sequencing utilized by PACBIO sequencing systems. Using this 
system, fragments that are >10,000bp can be sequenced and those long reads could be used for 
de novo haplotype assembly[56]. Currently this sequencing technology is not readily available 
for testing.  
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APPENDIX: TABLES 
Table 11: Haplotyping long range and inverse PCR primer sequences. 
Primer Name Sequence 
amp_1 LR forward TTTGATAATGACCTAATAATGATGGGTTTTATTT 
amp_1 LR reverse GATTAAATGCTACTTCTCTAGACTTACATAAGAA 
amp_1 circle forward AAGGCTCCAGTTCTCCCATA 
amp_1 circle reverse CACAATCCCTGTCCTCAAGGA 
amp_2 LR reverse TCATATGCATAATCAAAAAGTTTTCACATAGTT 
amp_2 circle reverse CTGGATTATGCCTGGCACCA 
amp_3 LR reverse GATTATATAAAGGAATTGCAAATGCCAACTATC 
amp_3 circle reverse GTTTATTGACAGTATACTCC 
amp_4 LR reverse AATATAATGGATGTTACAGATTTTGTCACTAAT 
amp_4 circle reverse AGAGACATAAAGATATTAAACAGAGTTACA 
amp_5 LR forward AATTTCATTCTGTTCTCAGTTTTCCTGGATTAT 
amp_5 circle forward GCTTCTGTATCTATATTCATC 
amp_8 LR forward TAAATGTTAGGGCAGGGAATATGTTACTATGAA 
amp_8B LR forward TGTGTGATGGTGGGTTCAGT 
amp_8 circle forward GCCAACTATCAAAGATATTGC 
amp_10 LR forward CAAACTCTAGGAACATATTTGATGACAGAGAC 
amp_10B_circle forward CTTACCAAACTGTACTGGTTTTCA 
amp_11 LR reverse CACAAGGAAAATGGACAAGGGG 
amp_11 circle reverse ACTCTACTCTTCCCTTCCTCTGT 
amp_14 LR forward CTTTATAATACTCTTGGCTCTCTTACGTTCTCT 
amp_14 LR reverse ATTTTCAATCCTGTTACATAATAACAATGG 
amp_14B_LR reverse TTGCCCCACTTTCCAAAGATT 
amp_14 circle forward ATAAGTGTGGTAGGAGCAGAGG 
amp_14 circle reverse TTGCAAATACAGTACATCTAACAAGA 
amp_17 LR forward TTATCTAATGGCCTATAAAATGTGACTTTC 
amp_17B_LR forward CCTTTAGCAATGCTTTCCTCAGT 
amp_17 LR reverse TAAATCCCCACACTTGTTGCTAATTG 
amp_17B_circle forward CTATTTTGCATAGCAGCTGTGGT 
amp_17 circle reverse TTACAGTATCCTGATATTGACTTATCGAG 
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Primer Name Sequence 
amp_19 LR forward GAAGTGCTTGAAGGCAGGTTTCATA 
amp_19B_LR forward CACAGAAGTGCTTGAAGGCAG 
amp_19 LR reverse AAGCAAAAATTGTCAGAAGTAGAAGTAGAT 
amp_19B_LR reverse TGTGTGCAGAGGAGAAAAAGAAAG 
amp_19B circle forward AATATTTTAATAATCAACCCCACAGTAAC 
amp_19 circle reverse TGTCCCCTTCAGTATTCTTGTCC 
amp_22 LR forward GTTCCTTATCTTCTATCTGTTTCTTACTGT 
amp_22 LR reverse AGAACAGTAATAAAGATGAAGACACAGTTC 
amp_22 circle forward TGGAGAAGCAAAAATTGTCAGAAGT 
amp_22 circle reverse GAGAATCCTATGTACTTGAGA 
amp_27 LR forward AACAAATACAAATCTGCACACATACAGAAATAA 
amp_27 circle forward ACAGATTTTGTCACTAATATCAAACACTTA 
amp_31 LR reverse AACAGAAGTATACAATAGATAGAATACCCTAGA 
amp_31 circle reverse GCATTCTTGAAGTCTCAGACCAAA 
amp_34 LR reverse AGTCAGACAGATCTGGATTTGAACC 
amp_34 circle reverse TTTTCACATTTGCAGATAAGGAAACTAAAG 
amp_36 LR forward TTTACTACCTATCTAACTCTTCGCATTCTT 
amp_36 circle forward ATAGAATACCCTAGAGGCTTTCAAAC 
amp_37 LR forward CCAACAATTACATGTATAAACAGAGAATCC 
amp_37B_circle forward GAGATAATTTCTTCATAACATTTAAAT 
amp_40 LR reverse CTTTACAATAGAACATTCTTACCTCTGCCA 
amp_40 circle reverse CCAGCAGTGACTACATGGAACA 
amp_44 LR forward ATATATTTAGTCCCCACAACTACCCTGG 
amp_44 circle forward CAACCTCCACCATTAACATCCTA 
 
 
Table 12: Long range PCR amplicon properties. 
  
Forward Long Range 
Primer 










amplicon 1 amp_1 LR forward amp_1 LR reverse 6 68 8480 
amplicon 2 amp_1 LR forward amp_2 LR reverse 0.5 68 269 
amplicon 3 amp_1 LR forward amp_3 LR reverse 0.5 68 1056 
amplicon 4 amp_1 LR forward amp_4 LR reverse 9 64 12462 
amplicon 5 amp_5 LR forward amp_3 LR reverse 0.5 68 950 
amplicon 6 amp_5 LR forward amp_1 LR reverse 6 68 8374 
amplicon 7 amp_5 LR forward amp_4 LR reverse 9 66 12356 
amplicon 8 amp_8 LR forward amp_1 LR reverse 5 64 7543 
Table 11 (continued) 
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Forward Long Range 
Primer 










amplicon 9 amp_8 LR forward amp_4 LR reverse 9 68 11525 
amplicon 10 amp_10 LR forward amp_4 LR reverse 3 66 4139 
amplicon 11 amp_1 LR forward amp_11 LR reverse 9 66 13296 
amplicon 12* amp_8 LR forward amp_11 LR reverse 9 66 12359 
amplicon 13 amp_10 LR forward amp_11 LR reverse 3.5 68 4973 
amplicon 14 amp_14 LR forward amp_14 LR reverse 3.5 62 5209 
amplicon 15B amp_10 LR forward amp_14B LR reverse 7 68 10084 
amplicon 17B* amp_17B LR forward amp_17 LR reverse 3 64 3317 
amplicon 18 amp_14 LR forward amp_17 LR reverse 6 68 8302 
amplicon 19 amp_19 LR forward amp_19 LR reverse 3 68 4429 
amplicon 20* amp_17 LR forward amp_19 LR reverse 5 66 7561 
amplicon 21 amp_14 LR forward amp_19 LR reverse 9 60 12570 
amplicon 22 amp_22 LR forward amp_22 LR reverse 3 64 4526 
amplicon 23B amp_17B LR forward amp_22 LR reverse 9 68 11989 
amplicon 24 amp_19 LR forward amp_22 LR reverse 6 68 8833 
amplicon 25 amp_5 LR forward amp_11 LR reverse 9 68 13190 
amplicon 26 amp_10 LR forward amp_17 LR reverse 9 62 13152 
amplicon 27 amp_27 LR forward amp_11 LR reverse 0.5 68 995 
amplicon 28 amp_27 LR forward amp_14 LR reverse 4 64 6081 
amplicon 29 amp_27 LR forward amp_17 LR reverse 7 68 9174 
amplicon 30 amp_27 LR forward amp_19 LR reverse 10 68 13442 
amplicon 31B amp_17B LR forward amp_31 LR reverse 7 68 9331 
amplicon 32 amp_19 LR forward amp_31 LR reverse 4 68 6155 
amplicon 33 amp_22 LR forward amp_31 LR reverse 2 66 1848 
amplicon 34 amp_19 LR forward amp_34 LR reverse 10 68 13458 
amplicon 35 amp_22 LR forward amp_34 LR reverse 7 68 9151 
amplicon 36 amp_36 LR forward amp_34 LR reverse 5 68 7401 
amplicon 37 amp_37 LR forward amp_34 LR reverse 3.5 68 4775 
amplicon 38 amp_14 LR forward amp_31 LR reverse 10 68 14296 
amplicon 39 amp_36 LR forward amp_22 LR reverse 2 66 2776 
amplicon 41 amp_22 LR forward amp_40 LR reverse 7 68 10034 
amplicon 42 amp_36 LR forward amp_40 LR reverse 6 68 8284 
amplicon 43 amp_37 LR forward amp_40 LR reverse 4 66 5658 
amplicon 44 amp_44 LR forward amp_40 LR reverse 0.5 68 1041 
* indicates use of GC phusion buffer rather than HF phusion buffer 
Table 12 (continued) 
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Table 13: Haplotyping inverse PCR amplicon properties. 
 
Circle Forward 





amplicon 1 amp_1 circle forward amp_1 circle reverse 66 202 
amplicon 2 amp_1 circle forward amp_2 circle reverse 60 215 
amplicon 3 amp_1 circle forward amp_3 circle reverse 60 162 
amplicon 4 amp_1 circle forward amp_4 circle reverse 64 197 
amplicon 5 amp_5 circle forward amp_3 circle reverse 56 181 
amplicon 6 amp_5 circle forward amp_1 circle reverse 62 221 
amplicon 7 amp_5 circle forward amp_4 circle reverse 60 216 
amplicon 8 amp_8 circle forward amp_1 circle reverse 66 220 
amplicon 9 amp_8 circle forward amp_4 circle reverse 66 215 
amplicon 10 amp_10B circle forward amp_4 circle reverse 66 217 
amplicon 11 amp_1 circle forward amp_11 circle reverse 66 161 
amplicon 12 amp_8 circle forward amp_11 circle reverse 62 179 
amplicon 13 amp_10 circle forward amp_11 circle reverse 66 181 
amplicon 14 amp_14 circle forward amp_14 circle reverse 66 264 
amplicon 15B amp_10B circle forward amp_14 circle reverse 66 289 
amplicon 17B amp_17B circle forward amp_17 circle reverse 66 231 
amplicon 18 amp_14 circle forward amp_17 circle reverse 64 221 
amplicon 19 amp_19B circle forward amp_19 circle reverse 66 190 
amplicon 20 amp_17B circle forward amp_19 circle reverse 66 177 
amplicon 21 amp_14 circle forward amp_19 circle reverse 66 191 
amplicon 22 amp_22 circle forward amp_22 circle reverse 66 253 
amplicon 23B amp_17B circle forward amp_22 circle reverse 62 234 
amplicon 24 amp_19B circle forward amp_22 circle reverse 62 223 
amplicon 25 amp_5 circle forward amp_11 circle reverse 62 180 
amplicon 26 amp_10B circle forward amp_17 circle reverse 66 221 
amplicon 27 amp_27 circle forward amp_11 circle reverse 62 229 
amplicon 28 amp_27 circle forward amp_14 circle reverse 60 312 
amplicon 29 amp_27 circle forward amp_17 circle reverse 62 269 
amplicon 30 amp_27 circle forward amp_19 circle reverse 66 239 
amplicon 31B amp_17B circle forward amp_31 circle reverse 66 182 
amplicon 32 amp_19B circle forward amp_31 circle reverse 66 171 
amplicon 33 amp_22 circle forward amp_31 circle reverse 64 201 
amplicon 34 amp_19B circle forward amp_34 circle reverse 66 211 
amplicon 35 amp_22 circle forward amp_34 circle reverse 66 241 
amplicon 36 amp_36 circle forward amp_34 circle reverse 66 194 
amplicon 37 amp_37B circle forward amp_34 circle reverse 62 218 
amplicon 38 amp_14 circle forward amp_31 circle reverse 66 172 









amplicon 41 amp_22 circle forward amp_40 circle reverse 66 246 
amplicon 42 amp_36 circle forward amp_40 circle reverse 66 199 
amplicon 43 amp_37B circle forward amp_40 circle reverse 62 223 
amplicon 44 amp_44 circle forward amp_40 circle reverse 64 252 
 
 
Table 14: Plasma inverse PCR primer sequences. 
Primer Name Sequence 
deltaF508 primer 5' ATGCCTGGCACCATTAAAGAAAATA 
deltaF508 reverse circle 2 5' CCACTGTGCTTAATTTTACCC 
rs1896887 forward 5' GACAGTATACTCCAAATAGTG 
rs1896887 reverse circle 5' CCCTGCCCTAACATTTACAGC  
rs718829 forward 5' CAATCCCTGTCCTCAAGGAGC 
rs718829 reverse circle 5' TTCCTAGAGTTTGGCCCAGTCCC 
rs2082056 forward 5' GAGACATAAAGATATTAAACAGAG 
rs2082056 reverse circle 5' CTGTATGTGTGCAGATTTG  
rs213934 forward 5' CTCTACTCTTCCCTTCCTCTGTTC 
rs213934 reverse circle 5' GAGAACGTAAGAGAGCCAAGAG  
rs2518873 forward 5' TGCAAATACAGTACATCTAAC 
rs2518873 reverse circle 5' CCATTAGATAATACTGAGGAAAGC  
rs213955 forward 5' CAGTATCCTGATATTGACTTATCG 
rs213955 reverse circle 5' ACCTGCCTTCAAGCACTTCT  
rs6949974 forward 5' CCCCTTCAGTATTCTTGTCCTT 
rs6949974 reverse circle 5' GATAAGGAACTACAGTCTATAC  
rs17547853 forward 5' GAAGTCTCAGACCAAATCCC 
rs17547853 reverse circle 5' GCGAAGAGTTAGATAGGTAGT  
rs213965 forward 5' CCTATGTACTTGAGATATAAGTAAGG 
rs213965 reverse circle 5' CTCTGTTTATACATGTAATTGTTGG  
rs213971 forward 5' GCAGATAAGGAAACTAAAGTTCAG 
rs213971 reverse circle 5' ATACCTTCCAGGGTAGTTGTG  
rs1042077 forward 5' ACATGGAACACATACCTTCGA 
rs1042077 reverse circle 5' CACTGCTGGTATGCTCTCCA  
 
 
Table 13 (continued) 
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Table 15: Sanger sequencing amplicon properties. 
Targeted 
Loci Forward Primer Reverse Primer 
Annealing 
Temp. 
rs213950 CATAGCAGAGTACCTGAAACAGGA AATGGTGCCAGGCATAATCCA 64 
rs1896887 TGTGTGATGGTGGGTTCAGT ATCTAATCCACGGTTTGCCC 66 
rs718829 TGTTTGGCACCAGGGATGT TGTTCTCCCTGTTGTTCACTC 66 
rs2082056 TCCGAACCTACCCCAAACAC CCTTCACTGATAGGAACTGACCA 66 
rs213934 AACACTCTCAGATACACGTTCACA ATTGGGTGGTTAGTGTCATTGTT 66 
rs2518873 CTTTAGCAATGCTTTCCTCAGT TTGCCCCACTTTCCAAAGATT 66 
rs213955 TGTGAGCAAGTGAATTCAAGCA AAATCCCCACACTTGTTGCTAAT 66 
rs6949974 TCTGTTTCTTACTGTCCCCTTCAG GGAAAAGAGACAGGGAAGGGA 66 
rs17547853 AAGGCGAGAGTTTACTACCTATC GTCCTTGACTCCTAGGCATTGT 66 
rs213965 GGGATCCATTATGTAGCTCTTGC AAAGATGAAGACACAGTTCCCA 66 
rs213971 TTAGTCCCCACAACTACCCT ACCCAACCTCCACCATTAACA 64 
rs1042077 ATGGAGAGCATACCAGCAGTG ACAATAGAACATTCTTACCTCTGCC 66 
 

















G1342 995,469 690,332 69.35% 630,565 63.34% 480,910 48.31% 
G1343 991,811 619,498 62.46% 528,968 53.33% 358,383 36.13% 
12-032 805,540 483,589 60.03% 436,288 54.16% 268,703 33.36% 
G1687 685,653 420,799 61.37% 376,351 54.89% 248,537 36.25% 
G1688 718,333 466,721 64.97% 412,056 57.36% 295,712 41.17% 
13-014 894,701 591,103 66.07% 524,764 58.65% 380,109 42.48% 
G1700 765,353 478,595 62.53% 408,538 53.38% 284,100 37.12% 
G1701 915,672 619,375 67.64% 539,220 58.89% 407,935 44.55% 
13-019 835,064 500,247 59.91% 455,387 54.53% 297,311 35.60% 
G1747 833,965 550,618 66.02% 454,417 54.49% 315,173 37.79% 
G1748 673,957 427,823 63.48% 391,441 58.08% 273,341 40.56% 
13-049 618,913 416,681 67.32% 375,115 60.61% 267,481 43.22% 
G1831 1,122,707 752,920 67.06% 699,677 62.32% 495,604 44.14% 
G1832 995,539 624,969 62.78% 530,235 53.26% 345,194 34.67% 
13-089 627,893 410,099 65.31% 369,650 58.87% 251,294 40.02% 
G1841 874,031 579,404 66.29% 529,983 60.64% 361,329 41.34% 
G1842 825,845 570,005 69.02% 522,076 63.22% 379,403 45.94% 
13-093 934,667 665,186 71.17% 610,475 65.31% 457,193 48.92% 
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Table 17: Allele counts per haplotyping sample. 
  
 Loci  
G1342 G1343 
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 379 200,735 201,114 0.19% 99.81% 134,588 365 134,953 99.73% 0.27% 
rs113993960 CTT/- 113,579 6 113,585 99.99% 0.01% 47,547 3 47,550 99.99% 0.01% 
rs1896887 G/C 26,635 48,535 75,170 35.43% 64.57% 25,324 20 25,344 99.92% 0.08% 
rs718829 C/A 268 157,260 157,528 0.17% 99.83% 141,474 329 141,803 99.77% 0.23% 
rs2082056 T/C 0 83 83 0.00% 100.00% 85 0 85 100.00% 0.00% 
rs213934 T/C 257 150,544 150,801 0.17% 99.83% 107,689 202 107,891 99.81% 0.19% 
rs2518873 C/T 23 19,734 19,757 0.12% 99.88% 31,548 25 31,573 99.92% 0.08% 
rs213955 A/G 47 13,047 13,094 0.36% 99.64% 3,225 11 3,236 99.66% 0.34% 
rs6949974 C/T 24,955 22,059 47,014 53.08% 46.92% 43,559 49 43,608 99.89% 0.11% 
rs17547853 G/A 76,538 71 76,609 99.91% 0.09% 79,037 60 79,097 99.92% 0.08% 
rs213965 T/A 0 43 43 0.00% 100.00% 27 0 27 100.00% 0.00% 
rs213971 G/A 2 1,309 1,311 0.15% 99.85% 1,271 0 1,271 100.00% 0.00% 




ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 47,384 45,309 92,693 51.12% 48.88% 60,383 50,690 111,073 54.36% 45.64% 
rs113993960 CTT/- 33,447 7 33,454 99.98% 0.02% 17,851 10,971 28,822 61.94% 38.06% 
rs1896887 G/C 35,520 442 35,962 98.77% 1.23% 19,584 111 19,695 99.44% 0.56% 
rs718829 C/A 46,283 41,831 88,114 52.53% 47.47% 71,085 63,412 134,497 52.85% 47.15% 
rs2082056 T/C 55 71 126 43.65% 56.35% 34 36 70 48.57% 51.43% 
rs213934 T/C 49,033 42,177 91,210 53.76% 46.24% 45,275 42,057 87,332 51.84% 48.16% 
rs2518873 C/T 14,743 9,378 24,121 61.12% 38.88% 18,756 2,529 21,285 88.12% 11.88% 
rs213955 A/G 7,269 6,966 14,235 51.06% 48.94% 8,702 7,998 16,700 52.11% 47.89% 
rs6949974 C/T 14,153 23,122 37,275 37.97% 62.03% 30,114 52 30,166 99.83% 0.17% 
rs17547853 G/A 53,001 40 53,041 99.92% 0.08% 74,742 64 74,806 99.91% 0.09% 
rs213965 T/A 5 6 11 45.45% 54.55% 7 8 15 46.67% 53.33% 
rs213971 G/A 635 539 1,174 54.09% 45.91% 342 282 624 54.81% 45.19% 
rs1042077 T/G 24,615 38,441 63,056 39.04% 60.96% 63,100 73 63,173 99.88% 0.12% 
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 Table 17 (continued) G1687 13-014
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 70,731 57,977 128,708 54.95% 45.05% 68,779 63,855 132,634 51.86% 48.14% 
rs113993960 CTT/- 13,893 10,799 24,692 56.27% 43.73% 22,560 17,404 39,964 56.45% 43.55% 
rs1896887 G/C 17,718 179 17,897 99.00% 1.00% 39,394 465 39,859 98.83% 1.17% 
rs718829 C/A 62,553 52,897 115,450 54.18% 45.82% 67,721 51,809 119,530 56.66% 43.34% 
rs2082056 T/C 15 36 51 29.41% 70.59% 30 41 71 42.25% 57.75% 
rs213934 T/C 19,743 18,721 38,464 51.33% 48.67% 65,334 79,618 144,952 45.07% 54.93% 
rs2518873 C/T 10,290 1,775 12,065 85.29% 14.71% 14,841 2,327 17,168 86.45% 13.55% 
rs213955 A/G 2,297 2,315 4,612 49.80% 50.20% 15,251 11,944 27,195 56.08% 43.92% 
rs6949974 C/T 45,017 52 45,069 99.88% 0.12% 47,495 77 47,572 99.84% 0.16% 
rs17547853 G/A 42,108 32 42,140 99.92% 0.08% 92,027 66 92,093 99.93% 0.07% 
rs213965 T/A 12 12 24 50.00% 50.00% 8 4 12 66.67% 33.33% 
rs213971 G/A 420 343 763 55.05% 44.95% 354 443 797 44.42% 55.58% 
rs1042077 T/G 65,069 73 65,142 99.89% 0.11% 94,229 163 94,392 99.83% 0.17% 
G1700 G1701 
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 54,679 40,742 95,421 57.30% 42.70% 69,076 52,947 122,023 56.61% 43.39% 
rs113993960 CTT/- 26,084 15,256 41,340 63.10% 36.90% 67,650 21,599 89,249 75.80% 24.20% 
rs1896887 G/C 23,870 115 23,985 99.52% 0.48% 85,267 228 85,495 99.73% 0.27% 
rs718829 C/A 51,352 40,814 92,166 55.72% 44.28% 68,371 53,726 122,097 56.00% 44.00% 
rs2082056 T/C 26 35 61 42.62% 57.38% 25 40 65 38.46% 61.54% 
rs213934 T/C 47,059 45,645 92,704 50.76% 49.24% 56,618 60,078 116,696 48.52% 51.48% 
rs2518873 C/T 21,998 2,875 24,873 88.44% 11.56% 10,702 1,369 12,071 88.66% 11.34% 
rs213955 A/G 1,389 1,290 2,679 51.85% 48.15% 20,156 20,420 40,576 49.67% 50.33% 
rs6949974 C/T 37,097 41 37,138 99.89% 0.11% 37,339 40 37,379 99.89% 0.11% 
rs17547853 G/A 73,118 45 73,163 99.94% 0.06% 95,530 81 95,611 99.92% 0.08% 
rs213965 T/A 26 10 36 72.22% 27.78% 8 7 15 53.33% 46.67% 
rs213971 G/A 410 306 716 57.26% 42.74% 393 314 707 55.59% 44.41% 
rs1042077 T/G 79,375 74 79,449 99.91% 0.09% 89,918 108 90,026 99.88% 0.12% 
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 Table 17 (continued) 13-019 G1747 
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 100,412 202 100,614 99.80% 0.20% 62,103 55,684 117,787 52.72% 47.28% 
rs113993960 CTT/- 32,781 3 32,784 99.99% 0.01% 50,549 7 50,556 99.99% 0.01% 
rs1896887 G/C 61,649 2 61,651 100.00% 0.00% 15,787 2 15,789 99.99% 0.01% 
rs718829 C/A 104,823 147 104,970 99.86% 0.14% 55,179 47,443 102,622 53.77% 46.23% 
rs2082056 T/C 983 0 983 100.00% 0.00% 23 32 55 41.82% 58.18% 
rs213934 T/C 126,227 140 126,367 99.89% 0.11% 63,566 62,179 125,745 50.55% 49.45% 
rs2518873 C/T 26,991 10 27,001 99.96% 0.04% 8,764 3,650 12,414 70.60% 29.40% 
rs213955 A/G 40,481 16 40,497 99.96% 0.04% 57,197 31 57,228 99.95% 0.05% 
rs6949974 C/T 30,086 25 30,111 99.92% 0.08% 17,555 15,750 33,305 52.71% 47.29% 
rs17547853 G/A 19,598 19 19,617 99.90% 0.10% 52,080 60 52,140 99.88% 0.12% 
rs213965 T/A 2,142 0 2,142 100.00% 0.00% 55 46 101 54.46% 45.54% 
rs213971 G/A 4,739 3 4,742 99.94% 0.06% 397 381 778 51.03% 48.97% 
rs1042077 T/G 28,641 34 28,675 99.88% 0.12% 34,873 24,195 59,068 59.04% 40.96% 
G1748 13-049
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 55,610 44,107 99,717 55.77% 44.23% 46,830 41,769 88,599 52.86% 47.14% 
rs113993960 CTT/- 67,647 30 67,677 99.96% 0.04% 52,417 11 52,428 99.98% 0.02% 
rs1896887 G/C 35,500 2 35,502 99.99% 0.01% 43,336 2 43,338 100.00% 0.00% 
rs718829 C/A 46,144 36,052 82,196 56.14% 43.86% 52,050 43,770 95,820 54.32% 45.68% 
rs2082056 T/C 45 126 171 26.32% 73.68% 69 115 184 37.50% 62.50% 
rs213934 T/C 52,750 58,508 111,258 47.41% 52.59% 57,002 59,775 116,777 48.81% 51.19% 
rs2518873 C/T 6,970 3,419 10,389 67.09% 32.91% 9,993 5,057 15,050 66.40% 33.60% 
rs213955 A/G 43,034 16 43,050 99.96% 0.04% 35,703 32 35,735 99.91% 0.09% 
rs6949974 C/T 16,394 15,895 32,289 50.77% 49.23% 17,067 10,136 27,203 62.74% 37.26% 
rs17547853 G/A 13,240 15,235 28,475 46.50% 53.50% 16,357 9,521 25,878 63.21% 36.79% 
rs213965 T/A 79 62 141 56.03% 43.97% 64 53 117 54.70% 45.30% 
rs213971 G/A 487 307 794 61.34% 38.66% 254 189 443 57.34% 42.66% 
rs1042077 T/G 15,403 16,420 31,823 48.40% 51.60% 18,612 12,456 31,068 59.91% 40.09% 
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Table 17 (continued) 
  
G1831 G1832 
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 77,885 59,419 137,304 56.72% 43.28% 77,321 41,484 118,805 65.08% 34.92% 
rs113993960 CTT/- 73,826 9 73,835 99.99% 0.01% 80,862 5 80,867 99.99% 0.01% 
rs1896887 G/C 104,006 7 104,013 99.99% 0.01% 68,114 405 68,519 99.41% 0.59% 
rs718829 C/A 73,411 58,614 132,025 55.60% 44.40% 62,374 53,300 115,674 53.92% 46.08% 
rs2082056 T/C 296 388 684 43.27% 56.73% 191 234 425 44.94% 55.06% 
rs213934 T/C 102,205 104,800 207,005 49.37% 50.63% 58,408 63,486 121,894 47.92% 52.08% 
rs2518873 C/T 8,131 4,054 12,185 66.73% 33.27% 15,929 7,175 23,104 68.94% 31.06% 
rs213955 A/G 43,328 19 43,347 99.96% 0.04% 3,241 2,977 6,218 52.12% 47.88% 
rs6949974 C/T 20,699 17,302 38,001 54.47% 45.53% 23,415 14,695 38,110 61.44% 38.56% 
rs17547853 G/A 106,653 79 106,732 99.93% 0.07% 49,383 51 49,434 99.90% 0.10% 
rs213965 T/A 183 145 328 55.79% 44.21% 116 94 210 55.24% 44.76% 
rs213971 G/A 511 385 896 57.03% 42.97% 576 433 1,009 57.09% 42.91% 




ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 48,179 44,191 92,370 52.16% 47.84% 367 120,653 121,020 0.30% 99.70% 
rs113993960 CTT/- 45,739 5 45,744 99.99% 0.01% 86,268 12 86,280 99.99% 0.01% 
rs1896887 G/C 51,021 5 51,026 99.99% 0.01% 70,920 11 70,931 99.98% 0.02% 
rs718829 C/A 32,088 27,455 59,543 53.89% 46.11% 230 97,350 97,580 0.24% 99.76% 
rs2082056 T/C 25 52 77 32.47% 67.53% 0 119 119 0.00% 100.00% 
rs213934 T/C 54,013 50,129 104,142 51.86% 48.14% 133 90,653 90,786 0.15% 99.85% 
rs2518873 C/T 15,013 8,161 23,174 64.78% 35.22% 32 24,684 24,716 0.13% 99.87% 
rs213955 A/G 35,541 17 35,558 99.95% 0.05% 54,919 42 54,961 99.92% 0.08% 
rs6949974 C/T 13,063 7,098 20,161 64.79% 35.21% 95 24,111 24,206 0.39% 99.61% 
rs17547853 G/A 30,134 36 30,170 99.88% 0.12% 196 86,987 87,183 0.22% 99.78% 
rs213965 T/A 90 66 156 57.69% 42.31% 0 197 197 0.00% 100.00% 
rs213971 G/A 414 266 680 60.88% 39.12% 1 780 781 0.13% 99.87% 
rs1042077 T/G 23,971 14,281 38,252 62.67% 37.33% 194 60,832 61,026 0.32% 99.68% 
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 Table 17 (continued) 
  
G1842 13-093 
ref alt total %ref %alt ref alt total %ref %alt 
rs213950 G/A 320 133,867 134,187 0.24% 99.76% 292 169,555 169,847 0.17% 99.83% 
rs113993960 CTT/- 70,906 14 70,920 99.98% 0.02% 111,115 5 111,120 100.00% 0.00% 
rs1896887 G/C 80,136 1,027 81,163 98.73% 1.27% 139,370 9 139,379 99.99% 0.01% 
rs718829 C/A 149 81,151 81,300 0.18% 99.82% 117 84,473 84,590 0.14% 99.86% 
rs2082056 T/C 0 130 130 0.00% 100.00% 0 94 94 0.00% 100.00% 
rs213934 T/C 136 121,794 121,930 0.11% 99.89% 107 125,400 125,507 0.09% 99.91% 
rs2518873 C/T 21 18,158 18,179 0.12% 99.88% 18 18,300 18,318 0.10% 99.90% 
rs213955 A/G 24,646 43,412 68,058 36.21% 63.79% 59,223 34 59,257 99.94% 0.06% 
rs6949974 C/T 59 35,834 35,893 0.16% 99.84% 50 43,878 43,928 0.11% 99.89% 
rs17547853 G/A 58,515 36,934 95,449 61.30% 38.70% 136 101,949 102,085 0.13% 99.87% 
rs213965 T/A 0 164 164 0.00% 100.00% 0 110 110 0.00% 100.00% 
rs213971 G/A 2 624 626 0.32% 99.68% 1 609 610 0.16% 99.84% 




















sample homozygous sample homozygous 
13039 24.44% 
 ref-alt 11899 22.30% 
 alt-ref 11705 21.94% 
 alt-alt 16717 31.33% 
rs213950-rs213934 ref-ref 
sample homozygous sample homozygous 
7342 29.29% 
 ref-alt 6880 27.45% 
 alt-ref 4776 19.06% 
 alt-alt 6066 24.20% 
rs718829_rs213934 ref-ref 
sample homozygous sample homozygous 
4001 26.57% 
 ref-alt 4507 29.93% 
 alt-ref 3057 20.30% 
 alt-alt 3495 23.21% 
rs718829_rs2518873 ref-ref 
sample homozygous sample homozygous 
909 42.02% 
 ref-alt 332 15.35% 
 alt-ref 568 26.26% 
 alt-alt 354 16.37% 
rs718829_rs213955 ref-ref 
sample homozygous sample homozygous 
383 29.67% 
 ref-alt 324 25.10% 
 alt-ref 266 20.60% 
 alt-alt 318 24.63% 
rs213934_rs2518873 ref-ref 
sample homozygous sample homozygous 
5546 29.63% 
 ref-alt 2621 14.00% 
 alt-ref 5888 31.45% 
 alt-alt 4664 24.92% 
rs213934_rs213955 ref-ref 
sample homozygous sample homozygous 
659 25.14% 
 ref-alt 582 22.21% 
 alt-ref 732 27.93% 
 alt-alt 648 24.72% 
rs2518873_rs213955 ref-ref 
sample homozygous sample homozygous 
105 40.08% 
 ref-alt 86 32.82% 
 alt-ref 35 13.36% 
 alt-alt 36 13.74% 
rs213955_rs213971 ref-ref 
sample homozygous sample homozygous 
32 37.21% 
  ref-alt 17 19.77% 
  alt-ref 16 18.60% 
















sample homozygous sample homozygous 
12 23.08% 
  ref-alt 7 13.46% 
  alt-ref 13 25.00% 
  alt-alt 20 38.46% 
rs6949974_rs1042077 ref-ref 13901 33.11% 
sample homozygous 
5075 18.81% 
  ref-alt 8351 19.89% 3581 13.27% 
  alt-ref 8645 20.59% 3758 13.93% 




Table 19: Haplotype category counts at heterozygous loci for trio 2. 
SNP Pair 
Category 











rs213950-rs113993960 ref-ref 5338 35.48% 3497 35.16% 1834 33.07% 
  ref-alt 1851 12.30% 1285 12.92% 187 3.37% 
  alt-ref 1710 11.37% 994 9.99% 230 4.15% 
  alt-alt 6145 40.85% 4170 41.93% 3295 59.41% 
rs213950-rs718829 ref-ref 32481 32.16% 26319 30.55% 22425 32.65% 
  ref-alt 23394 23.16% 19986 23.20% 14523 21.14% 
  alt-ref 21837 21.62% 19099 22.17% 14128 20.57% 
  alt-alt 23291 23.06% 20738 24.07% 17614 25.64% 
rs213950-rs213934 ref-ref 2395 26.01% 2742 25.87% 13147 23.36% 
  ref-alt 3010 32.69% 2986 28.17% 15659 27.83% 
  alt-ref 1652 17.94% 1843 17.39% 9794 17.41% 
  alt-alt 2152 23.37% 3030 28.58% 17669 31.40% 
rs113993960-rs718829 ref-ref 42 34.43% 234 40.41% 73 58.40% 
  ref-alt 47 38.52% 96 16.58% 36 28.80% 
  alt-ref 17 13.93% 83 14.34% 9 7.20% 
  alt-alt 16 13.11% 166 28.67% 7 5.60% 
rs113993960_rs213934 ref-ref 3154 50.27% 6925 51.76% 5046 24.97% 
  ref-alt 627 9.99% 1341 10.02% 1536 7.60% 
  alt-ref 505 8.05% 1134 8.48% 1259 6.23% 
  alt-alt 1988 31.69% 3980 29.75% 12367 61.20% 
        















rs718829_rs213934 ref-ref 19 31.15% 8876 28.48% 10923 40.85% 
  ref-alt 10 16.39% 7653 24.55% 4509 16.86% 
  alt-ref 7 11.48% 6012 19.29% 3473 12.99% 
  alt-alt 25 40.98% 8627 27.68% 7836 29.30% 
rs718829_rs213955 ref-ref 26 30.23% 243 16.91% 893 33.36% 
  ref-alt 28 32.56% 577 40.15% 647 24.17% 
  alt-ref 18 20.93% 473 32.92% 506 18.90% 
  alt-alt 14 16.28% 144 10.02% 631 23.57% 
rs213934_rs213955 ref-ref 64 26.12% 41 25.31% 2769 31.82% 
  ref-alt 52 21.22% 41 25.31% 2002 23.01% 
  alt-ref 66 26.94% 48 29.63% 2273 26.12% 



















rs213950_rs113993960 ref-ref 8210 43.26% 7569 36.91% 
sample homozygous   ref-alt 2952 15.55% 2663 12.99% 
  alt-ref 2797 14.74% 2471 12.05% 
  alt-alt 5020 26.45% 7802 38.05% 
rs213950_rs718829 ref-ref 13915 28.63% 26733 35.22% 
sample homozygous   ref-alt 12063 24.82% 17923 23.62% 
  alt-ref 11534 23.73% 16581 21.85% 
  alt-alt 11086 22.81% 14657 19.31% 
rs213950_rs213934 ref-ref 4742 22.45% 3509 19.97% 
sample homozygous   ref-alt 6738 31.91% 5662 32.23% 
  alt-ref 3682 17.44% 2980 16.96% 
  alt-alt 5956 28.20% 5417 30.83% 
rs113993960_rs718829 ref-ref 47 40.52% 467 39.54% 
sample homozygous   ref-alt 37 31.90% 315 26.67% 
  alt-ref 15 12.93% 182 15.41% 
  alt-alt 17 14.66% 217 18.37% 















rs113993960_rs213934 ref-ref 6337 39.75% 7906 45.54% 
sample homozygous   ref-alt 2553 16.01% 1257 7.24% 
  alt-ref 2141 13.43% 830 4.78% 
  alt-alt 4912 30.81% 7367 42.44% 
rs718829_rs213934 ref-ref 4819 25.36% 5569 23.54% 
sample homozygous 
  ref-alt 5780 30.42% 5967 25.23% 
  alt-ref 3811 20.06% 5825 24.63% 
  alt-alt 4592 24.17% 6293 26.60% 
rs718829_rs213955 ref-ref 11 24.44% 450 26.10% 
sample homozygous   ref-alt 11 24.44% 495 28.71% 
  alt-ref 16 35.56% 383 22.22% 
  alt-alt 7 15.56% 396 22.97% 
rs213934_rs213955 ref-ref 144 21.79% 7582 29.96% 
sample homozygous   ref-alt 178 26.93% 6188 24.46% 
  alt-ref 155 23.45% 6290 24.86% 
  alt-alt 184 27.84% 5243 20.72% 
rs213955_rs213965 ref-ref 10 55.56% 0 0.00% 
sample homozygous   ref-alt 5 27.78% 0 0.00% 
  alt-ref 0 0.00% 0 0.00% 
  alt-alt 3 16.67% 0 0.00% 
rs213955_rs213971 ref-ref 46 47.42% 37 28.24% 
sample homozygous   ref-alt 18 18.56% 31 23.66% 
  alt-ref 21 21.65% 35 26.72% 
  alt-alt 12 12.37% 28 21.37% 
 
 
Table 21: Haplotype category counts at heterozygous loci for trio 5. 
SNP Pair 
Category 










rs213950_rs718829 ref-ref 20253 34.86% 10686 26.57% 9283 30.29% 
  ref-alt 13547 23.32% 9928 24.69% 7050 23.00% 
  alt-ref 12661 21.79% 9494 23.61% 6864 22.39% 
  alt-alt 11637 20.03% 10104 25.13% 7454 24.32% 
rs213950_rs213934 ref-ref 6060 27.79% 5574 19.78% 6030 29.92% 
  ref-alt 7040 32.28% 16088 57.09% 4769 23.67% 
  alt-ref 3919 17.97% 3119 11.07% 3345 16.60% 
  alt-alt 4790 21.96% 3400 12.06% 6008 29.81% 














rs718829_rs213934 ref-ref 12063 26.45% 12221 29.61% 3690 26.63% 
  ref-alt 13250 29.05% 12069 29.24% 3958 28.57% 
  alt-ref 9466 20.76% 8416 20.39% 2946 21.26% 
  alt-alt 10825 23.74% 8570 20.76% 3261 23.54% 
rs718829_rs2518873 ref-ref 767 35.54% 2801 39.42% 1615 38.16% 
  ref-alt 375 17.38% 1178 16.58% 660 15.60% 
  alt-ref 678 31.42% 2173 30.58% 1361 32.16% 




sample homozygous   ref-alt 25 6.79% 
  alt-ref 14 3.80% 
  alt-alt 124 33.70% 
rs2082056_rs213934 ref-ref 121 22.45% 57 21.27% 6 16.67% 
  ref-alt 118 21.89% 67 25.00% 5 13.89% 
  alt-ref 143 26.53% 67 25.00% 7 19.44% 
  alt-alt 157 29.13% 77 28.73% 18 50.00% 
rs213934_rs2518873 ref-ref 2378 31.95% 4889 38.47% 4764 30.84% 
  ref-alt 1267 17.02% 1954 15.37% 2505 16.22% 
  alt-ref 2415 32.44% 3802 29.92% 4405 28.52% 




sample homozygous   ref-alt 42 23.73% 
  alt-ref 52 29.38% 




sample homozygous   ref-alt 10 21.74% 
  alt-ref 12 26.09% 




sample homozygous   ref-alt 248 35.33% 
  alt-ref 85 12.11% 




sample homozygous   ref-alt 32 18.18% 
  alt-ref 57 32.39% 
  alt-alt 41 23.30% 
      
      
      














rs6949974_rs213971 ref-ref 20 32.26% 48 42.48% 9 22.50% 
  ref-alt 8 12.90% 24 21.24% 6 15.00% 
  alt-ref 30 48.39% 19 16.81% 13 32.50% 
  alt-alt 4 6.45% 22 19.47% 12 30.00% 
rs6949974_rs1042077 ref-ref 10929 33.57% 13103 47.00% 7631 46.17% 
  ref-alt 6934 21.30% 5021 18.01% 3442 20.82% 
  alt-ref 6802 20.89% 5220 18.72% 3379 20.44% 
  alt-alt 7895 24.25% 4536 16.27% 2077 12.57% 




ref-alt 28 27.72% 12 30.77% 
 
alt-ref 21 20.79% 10 25.64% 
 
alt-alt 26 25.74% 8 20.51% 
rs213971_rs1042077 ref-ref 143 27.45% 158 32.51% 146 35.27% 
 
ref-alt 136 26.10% 121 24.90% 113 27.29% 
 
alt-ref 123 23.61% 117 24.07% 86 20.77% 




Table 22: Haplotype category counts at heterozygous loci for trio 5. 
SNP Pair 
Category 














sample homozygous   ref-alt 4917 11.08% 
  alt-ref 20742 46.74% 
  alt-alt 10832 24.41% 
 
Table 21 (continued) 
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